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Summary 
 
The TOR proteins play a central role in the control of cell growth. TOR proteins are the 
founding members of the phosphatidylinositol-related kinase (PIKK) family of protein 
kinases. In S. cerevisiae there are two TOR proteins, TOR1 and TOR2. TOR1 and 
TOR2 regulate cell growth via a rapamycin-sensitive pathway controlling translation, 
transcription, nutrient uptake, ribosome biogenesis and autophagy. TOR2 also has a 
unique, rapamycin-insensitive function, which is the control of the actin cytoskeleton. 
Recently, it has been found that the TOR proteins exist in two distinct complexes, TOR 
complex 1 (TORC1) and TOR complex 2 (TORC2). While TORC1 mediates the 
rapamycin-sensitive pathway, TORC2 is responsible for the control of the actin 
cytoskeleton. TORC1 comprises three proteins, TOR1 or TOR2, KOG1 and LST8. 
TORC2 consists of five proteins, TOR2, AVO1, AVO2, AVO3 and LST8. Thus, these 
structurally and functionally distinct TOR complexes account for the diversity of TOR 
signaling in yeast. Here we focused on the characterization of TORC2. Our studies 
suggest that TORC2 exists in an oligomeric state and that AVO1 and likely AVO3 act as 
scaffold proteins required for the integrity of TORC2. We also found that AVO1 plays a 
role as an adaptor protein mediating efficient phosphorylation of substrates. LST8 in turn 
appears to modulate TOR2 kinase activity possibly by binding directly to the TOR2 
kinase domain. LST8 is common to both TORC1 and TORC2 and may therefore be 
important to respond to upstream signaling factors. 
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1. Introduction 
 
1. 1. Rapamycin and the discovery of TOR 
 
The macrolide rapamycin is produced by a strain of Streptomyces hygroscopius which 
was originally isolated from a soil sample collected from Rapa-Nui (Easter Island). 
Rapamycin possesses potent antifungal, immunosuppressant, and antitumor properties 
(Hidalgo and Rowinsky, 2000). Inside a cell rapamycin binds to FKBP12 (FK506-
binding protein). FKBP12 is a cytoplasmic petidyl-prolyl cis-trans isomerase that also 
binds FK506 (a potent immunosuppressant structurally related to rapamycin) (Heitman 
et al., 1991b; Schreiber, 1991). Disruption of FPR1, the gene encoding FKBP12 in 
yeast, revealed that FKBP12 is not essential for viability, and frp1 mutant cells were 
resistant to rapamycin toxicity (Heitman et al., 1991a; Heitman et al., 1991b). In 
addition, since rapamycin analogues could still bind and inhibit the isomerase activity of 
FKBP12 but could not act as immunosuppressants lead to the assumption that 
FKBP12 is not the target through which rapamycin inhibits cell growth (Bierer et al., 
1990). Rapamycin rather forms a complex with FKBP12, which then acts on another 
target essential for growth. To identify this target spontaneous, rapamycin-resistant 
yeast mutants were selected. Three genes were identified in the screen, FPR1 and two 
novel genes that were named TOR1 and TOR2 (target of rapamycin) (Heitman et al., 
1991a). While the mutations conferring rapamycin resistance in FPR1 were loss-of-
function mutations, the mutations in TOR1 and TOR2 were gain-of-function mutations. 
These dominant TOR1 and TOR2 alleles confer complete resistance to the antifungal 
activity of rapamycin because they are no longer bound by FKBP12-rapamycin (Chen 
et al., 1995; Choi et al., 1996; Lorenz and Heitman, 1995; Stan et al., 1994). 
 
The TOR proteins are highly conserved through eukaryote evolution. TOR was 
identified in all eukaryotes examined including Schizosaccharomyces pombe, 
Cryptococcus neoformans, Ashbya gossypii, Arabidopsis thaliana, Drosophila 
melanogaster, Caenorhabditis elegans and mammals. Interestingly, higher eukaryotes 
contain only a single TOR gene, whereas the fungi, S. cerevisiae, S. pombe and C. 
neoformans, have two TOR genes (Crespo and Hall, 2002). 
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1. 2. Domain structure of TOR 
 
The highly homologous (67%) TOR1 and TOR2 proteins are large proteins with a 
molecular mass of 280 kDa. Both proteins contain a region in their C-terminus that is 
structurally related to lipid kinases, especially to phosphatidylinositol 3-kinase (PI3K) 
and phosphatidylinositol 4-kinase (Cafferkey et al., 1994; Helliwell et al., 1994; Kunz et 
al., 1993). Based on this homology TOR has been grouped in a novel class of 
phosphatidylinositol (PI) kinases, the PI kinase-related kinases (PIKK) (Keith and 
Schreiber, 1995). The PIKK family includes the yeast MEC1, TEL1 and RAD3 proteins 
and the mammalian ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia 
related) and DNA-PK (DNA-dependent protein kinase) (Abraham, 2001). PIKK family 
members are very large proteins and several members have been implicated to 
function in the cell cycle checkpoint function.  Despite their homology to PI kinases 
none of its members have been shown to exhibit lipid kinase activity, in fact PIKK are 
Ser/Thr kinases.  
 
The N-terminus of TOR contains two large blocks of up to 20 tandemly repeated HEAT 
repeats (named for Huntingtin, elongation factor 3, A subunit of protein phosphatase 
2A and TOR1) (Andrade and Bork, 1995). Each HEAT motif comprises approximately 
40 amino acids that form antiparallel α-helices (Groves and Barford, 1999; Perry and 
Kleckner, 2003). This structure provides a large exposed surface with a hydrophobic 
nature that can mediate protein-protein interaction. It has been demonstrated the HEAT 
repeats are important for protein-protein interaction and that the HEAT repeats of 
TOR2 are required for the localization of TOR2 to membranes (Chook and Blobel, 
1999; Kim et al., 2002; Kunz et al., 2000). The HEAT domain is followed by a FAT 
domain. This domain is found in all PIK-related kinases and is accompanied by a small 
FATC domain, which is located at the very C-terminus of the PIKKs. The FAT and 
FATC domains may serve as scaffold or as protein-protein interaction domain (Alarcon 
et al., 1999; Bosotti et al., 2000). Following the FAT domain is the FKBP-rapamycin-
binding domain (FRB), which is the direct binding target for the FKBP-rapamycin 
complex (Fig. 1.1.). 
 
 
 
 
2
1. 3. TOR signaling in higher eukaryotes 
 
TOR plays a central role in the control of cell growth. Genetic studies of Drosophila 
TOR (dTOR) revealed that cells mutant for dTOR were reduced in size at all stages of 
the cell cycle leading to a fly with a reduced body size (Oldham et al., 2000; Zhang et 
al., 2000). In addition, TOR mutant animals had a growth arrest phenotype similar to 
flies that have been starved for amino acids suggesting that TOR controls cell growth in 
response to nutrients. 
 
What are the growth-related readouts of TOR? mTOR has been reported to control 
various readouts including translation, transcription, PKC signaling and autophagy 
(Fingar and Blenis, 2004). So far all the growth-related readouts of TOR in higher 
eukaryotes appear to be sensitive to rapamycin. Nevertheless, a recent report 
suggests that mTOR controls trafficking of amino acid transporters in a rapamycin-
independent manner indicating that mTOR also exerts rapamycin-insensitive functions 
(Edinger et al., 2003). Currently, the best characterized downstream effectors of mTOR 
are the translational regulators, p70S6K and 4E-BP1. 
 
 
1. 3. 1. Downstream effectors of mTOR 
 
p70S6K1  
p70S6K1 is activated by various extracellular signals. Activated p70S6K1 
phosphorylates the 40S ribosomal protein S6 leading to an upregulation of translation 
of a subset of mRNA that contain a terminal oligopyrimidine (TOP) tract at their 5’-end 
(Jefferies et al., 1997). These 5’TOP mRNAs encode components of the translational 
apparatus, such as ribosomal proteins and elongation factors, which are predicted to 
account for 15-20% of total cellular mRNA (Meyuhas, 2000). Therefore, it is thought 
that activation of p70S6K leads to general upregulation of translational capacity. 
 
p70S6K is activated by multiple phosphorylation events that are regulated by mTOR- 
and growth factor-dependent signaling pathways. At least eight phosphorylation sites 
have been implicated in the regulation of p70S6K. PDK1 (phospholipid-dependent 
protein kinase), a downstream kinase of the growth-factor dependent PI3K signaling 
pathway, phosphorylates Thr229, which is located in the activation loop of the kinase 
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domain (Alessi et al., 1998). Activation of p70S6K is dependent on the phosphorylation 
of Thr229 (Dennis et al., 1996). Phosphorylation of two other sites Ser371 and Thr389 
are also essential for p70S6K activation and are directly phosphorylated by mTOR in 
vitro (Burnett et al., 1998; Dennis et al., 1996; Pearson et al., 1995; Saitoh et al., 2002). 
Thr389 as well as Thr229 and Ser404 represent a motif in which the phosphorylated 
Ser or Thr is followed by a hydrophobic residue whereas Ser371 is flanked by Pro. 
p70S6K contains an additional four phosphorylation sites at the C-terminus (Ser 411, 
418, 421, and Thr424) exhibiting a Ser/Thr-Pro motif. These four sites lie in the 
autoinhibitory pseudosubstrate domain and they are not essential for kinase activity. In 
its inactive state the C-terminal  pseudosubstrate domain of p70S6K is thought to 
interact with the N-terminus and thereby inhibit the catalytic activity (Martin and Blenis, 
2002). Phosphorylation of the four sites in this domain appears to facilitate the 
phosphorylation Thr389, the mTOR phosphorylation site (Avruch et al., 2001). 
Phosphorylation of Thr389 has been proposed to create a binding site for PDK1, thus 
facilitating in the phosphorylation of Thr229 (Biondi et al., 2001). Therefore, it is thought 
that prior phosphorylation of p70S6K at the hydrophobic motif (Thr389) promotes 
phosphorylation of the activation loop (Thr229) by PDK1 required for activation of 
p70S6K. Treatment with rapamycin results in dephosphorylation and inactivation of 
p70S6K. Thr389 is the major rapamycin-sensitive phosphorylation site but Thr229 and 
Ser404 as well as two Ser/Thr-Pro sites (Ser371 and Ser411) are also 
dephosphorylated upon treatment with rapamycin (Han et al., 1995; Pearson et al., 
1995).  
 
Recently, a TOR signaling (TOS) motif has been identified at the N-terminus of p70S6K 
(Schalm and Blenis, 2002). The TOS motif consists of five residues and is 
characterized by an aromatic residue followed by alternating hydrophobic and acidic 
residues. A functional TOS motif is required for efficient phosphorylation and activation 
of p70S6K as mutation of the TOS motif mimics the effect of rapamycin on p70S6K 
phosphorylation. 
 
 
4E-BP1 
4E-BP1 (4E-binding protein) inhibits cap-dependent translation by binding to eukaryotic 
initiation factor 4E (eIF4E). eIF4E is the subunit of the tripartite eukaryotic initiation 
factor 4 (eIF4F) complex that recognizes the cap, m7GpppX (in which m is a methyl 
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group and X any nucleotide), which is present at the 5’end of mRNAs. The two other 
subunits of eIF4F are eIF4G and eIF4A. eIF4A is an RNA helicase which unwind the 
RNA. eIF4G is a scaffolding protein binding to eIF4E, eIF4A, eIF3, and the poly(A)-
binding protein, and thus bridges the 40S ribosome to the mRNA. Cap-dependent 
translation is regulated by the eIF4E-binding proteins (4E-BPs), which compete with 
eIF4G for binding to eIF4E. Binding of 4E-BP1 to eIF4E is regulated by 
phosphorylation. Hypophosphorylated 4E-BP1 binds to eIF4E, whereas 
hyperphosphorylated 4E-BP1 abolishes this interaction enabling eIF4E to associate 
with eIF4G. Thus, phosphorylation of 4E-BP1 allows the positioning of the translation 
machinery on the 5’ end of the mRNA (Gingras et al., 2001; Raught et al., 2001).  
 
The TOR signaling pathway, as well as the PI3K pathway are involved in the regulation 
of the 4E-BP1 phosphorylation (Gingras et al., 2001). Phosphorylation of 4E-BP1 
occurs in a hierarchical manner involving at least six phosphorylation sites, four of 
which are regulated by mTOR signaling and contain a Ser/Thr-Pro motif (Gingras et al., 
1999; Mothe-Satney et al., 2000). Phosphorylation of Thr37 and Thr46 is required for 
the subsequent mitogen-responsive phosphorylation of Thr70 and Ser65 and the 
subsequent release of eIF4E. While mTOR has been shown to directly phosphorylate 
Thr37 and Thr46 in vitro the kinase regulating Thr70 and Ser65 is unknown (Brunn et 
al., 1997; Burnett et al., 1998; Gingras et al., 1999). Since phosphorylation of Ser65 
and Thr70 is more sensitive to rapamycin than phosphorylation of Thr37 and Thr47 it 
has been proposed that phosphorylation of Ser65 and Thr70 might be regulated by a 
mTOR-dependent kinase or a mTOR-inhibited phosphatase (Gingras et al., 2001). 
 
Two domains in 4E-BP1 have been shown to be required for its efficient 
phosphorylation. In addition to the TOS motif located at the C-terminus (Schalm and 
Blenis, 2002), 4E-BP1 contains a domain at the N-terminus, that is composed of the 
four amino acids Arg-Ala-Ile-Pro, called RAIP motif (Tee and Proud, 2002). Recently, it 
has been reported that raptor, a protein that interacts with mTOR binds 4E-BP1 as well 
as p70S6K through their TOS motifs bringing these two substrates in proximity of 
mTOR kinase (Beugnet et al., 2003; Choi et al., 2003; Nojima et al., 2003; Schalm et 
al., 2003). Since raptor does not appear to mediate interaction of 4E-BP1 via the RAIP 
motif it has been suggested that by interaction with the RAIP motif other proteins may 
recruit proximal kinases to 4E-BP1 (Proud, 2004).   
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1. 3. 2. Regulators of mTOR, what is upstream? 
 
How is mTOR regulated and what is upstream of mTOR? Three major inputs have 
been implicated in mTOR signaling, all of which converge on the phosphorylation of 
mTOR target proteins p70S6K and 4E-BP1. First, mTOR activation is dependent on 
the growth factor signaling pathway. Second, mTOR appears to be regulated by 
nutrients, especially amino acids. Third, energy levels have been recently shown to be 
important for regulation of mTOR activity (illustrated in Fig. 1.2.). 
 
 
Growth factors 
The mTOR pathway responds to growth factors via the phophatidylinositol 3-kinase 
(PI3K) pathway. Binding of insulin or insulin-like growth factors (IGFs) to their receptors 
leads to receptor dimerimerzation and autophosphorylation which triggers recruitment 
and phosphorylation of insulin receptor substrates (IRS) to generate a docking site for 
PI3K at the membrane. PI3K bound to IRS converts phosphatidylinositol-4,5-phosphate 
(PIP2) in the cell membrane to phosphatidylinositol-3,4,5-phosphate (PIP3). The 
conversion of PIP2 to PIP3 is negatively controlled by the lipid phosphatase PTEN. 
Once generated PIP3 recruits PDK1 and Akt through their pleckstrin-homology (PH) 
domain to the membrane. Membrane-bound Akt in turn is phosphorylated and 
activated by PDK1 (Alessi, 2001). 
 
How does the growth factor pathway regulate mTOR activity? mTOR appears to be 
controlled by Akt and the Tuberous sclerosis proteins, TSC1 (hamartin) and TSC2 
(tuberin). TSC1 contains two coiled-coil domains, whereas TSC2 possesses in addition 
to a coiled-coil domain a region that is similar to the catalytic domain of GTPase 
activating proteins (GAP). Through interaction of their coiled-coil domains TSC1 and 
TSC2 form a complex (van Slegtenhorst et al., 1998). It has been shown that 
overexpression of TSC1-TSC2 blocks TOR signaling leading to the inhibition of 
p70S6K and 4E-BP1 phosphorylation. Further, TSC2 is phosphorylated by Akt in 
response to insulin which destabilizes TSC2 and results in the inactivation of TSC2 and 
the subsequent disruption of TSC1-TSC2 (Gao et al., 2002; Inoki et al., 2002; Manning 
et al., 2002; Potter et al., 2003; Tee et al., 2002). Therefore, TSC1-TSC2 appears to 
function downstream of Akt and upstream of mTOR to negatively regulate p70S6K and 
4E-BP1. However, Akt is also able to control mTOR through direct phosphorylation of 
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mTOR (Nave et al., 1999). The significance of this phosphorylation remains unclear 
since substitution of the phosphorylated Ser to Ala does not affect the ability of mTOR 
to activate p70S6K (Sekulic et al., 2000).  
 
How does TSC1-TSC2 regulate mTOR? Recently, it has been found TSC1-TSC2 
controls mTOR via Rheb (Ras homolog enriched in brain), a Ras-related small GTPase 
(Garami et al., 2003; Inoki et al., 2003a; Tee et al., 2003). Overexpression of Rheb 
enhances mTOR signaling towards p70S6K and 4E-BP1 and activates mTOR even in 
absence of growth factors or amino acids. On the other hand, the effect of Rheb on 
p70S6K and 4E-BP1 phosphorylation is blocked by overexpression of TSCs indicating 
that TSCs are involved in the activation of Rheb (Garami et al., 2003; Inoki et al., 
2003a; Tee et al., 2003). It has been demonstrated that TSC2 through its GAP domain 
stimulates the intrinsic GTPase activity of Rheb resulting in the conversion from active 
GTP-bound Rheb to inactive GDP-bound Rheb (Inoki et al., 2003a; Tee et al., 2003; 
Zhang et al., 2003). The activation of Rheb is dependent on insulin as evidenced by the 
fact that insulin treatment leads to an increase of GTP-bound Rheb likely through 
activation of the PI3K/Akt signaling pathway that phosphorylates and inhibits TSC2 
(Garami et al., 2003). Thus, the growth factor activated PI3K pathway impinges on 
mTOR via a pathway consisting of the proteins Akt, TSC1-TSC2 and Rheb. 
 
Phosphatidic acid (PA) generated by mitogen-stimulated phospholipase D (PLD) was 
shown to play a role in mTOR signaling since PA stimulates phosphorylation of p70S6 
and 4E-BP1 in an mTOR-dependent but PI3K-independent manner. PA may exert its 
effects by direct binding to the FRB domain in mTOR (Fang et al., 2001). The 
significance of PA in mTOR signaling however has to be elucidated. 
 
Nutrients 
Nutrients in the form of amino acids have been implicated in the regulation of mTOR 
signaling. Starvation for amino acids, in particular branched amino acids like leucine, 
results in a rapid dephosphorylation of p70S6K and 4E-BP1 (Hara et al., 1998; Wang 
et al., 1998; Xu et al., 1998). Readdition of amino acids restores p70S6K and 4E-BP1 
in an mTOR-dependent manner. Abundant leucine increases mTOR activity and the 
stimulatory effect of leucine on mTOR is not blocked by the PI3K inhibitor wortmannin. 
Additionally, leucine does not change the activities of PI3K and Akt indicating that 
leucine signals to mTOR by a mechanism that is independent of the growth factor 
7
induced PI3K signaling pathway. How amino acids are sensed by mTOR is unknown. 
However, TSC1-TSC2 and Rheb have been implicated in the nutrient sensing process 
because overexpression of Rheb can bypass the need for amino acids to activate 
mTOR signaling and loss of TSC1-TSC2 renders cells resistant to amino acid 
starvation suggesting that mTOR may sense amino acids via TSC1-TSC2/Rheb 
signaling network (Gao et al., 2002; Saucedo et al., 2003). 
 
Energy 
A high rate of translation is coupled to a high energy demand. ATP depletion causes a 
decrease in p70S6K and 4E-BP1 phosphorylation resulting in the inhibition of 
translation. It was suggested that mTOR may sense ATP levels since it has a high KM 
(1mM) for ATP (Dennis et al., 2001). However, the ATP levels do not change 
drastically in a cell and the cellular concentration of ATP is higher than the predicted KM 
of ATP for mTOR. Therefore, small changes of the ATP concentration could not be 
sensed by mTOR (Proud, 2002). mTOR may sense the energy status of a cell through 
the AMP-activated protein kinase (AMPK) (Inoki et al., 2003b). AMPK is activated 
under low cellular energy conditions (high AMP/ATP ratio). Activated AMPK 
downregulates high energy demanding processes like protein synthesis and stimulates 
ATP generation processes, such as glycogenolysis. AMP as well as the drug AICAR, 
an AMP analogue are able the activate AMPK (Hardie and Hawley, 2001). Activation of 
AMPK by AICAR has been demonstrated to inhibit phosphorylation of p70S6K and 4E-
BP1 via the mTOR pathway (Kimura et al., 2003). Recently, it has been reported that 
activated AMPK directly phosphorylates TSC2 and that energy starvation-induced 
dephosphorylation of p70S6K is dependent on TSC2 (Inoki et al., 2003b). mTOR may 
therefore be regulated by AMP/ATP ratio via AMPK and TSC2. 
 
Another cellular component inorganic polyphosphate (poly P) has been implicated in 
the regulation of mTOR. Poly P are linear polymers of many hundreds of phosphates 
present in all organisms from bacteria to animals. In E. coli poly P is increased in 
response to starvation and stimulates degradation of ribosomal proteins by activation of 
the Lon protease (Kuroda et al., 2001). Poly P has been reported to stimulate mTOR 
activity in vitro and expression of yeast polyphosphatase in human cells leads to 
inhibition of the insulin or amino acid-stimulated phosphorylation of 4E-BP1 suggesting 
a role for poly P in mammalian cells (Wang et al., 2003). 
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1. 3. 3. TOR and control of cell growth 
 
Genetic studies in Drosophila revealed that the insulin receptor signaling pathway and 
the TOR signaling pathway play an important role in the control of cell growth. Loss-of-
function mutations of components that act positively in the pathway such as CHICO 
(the insulin receptor substrate homologue), dPI3K and dAkt results in smaller flies with 
fewer and smaller cells. Loss-of-function mutations of negative regulators, such as 
dPTEN or dTSCs result in enhanced growth and bigger flies. Importantly, mutation of 
dTOR or dS6K leads to smaller flies without affecting the cell number indicating that 
TOR controls the size of individual cells but not proliferation (Saucedo and Edgar, 
2002; Stocker and Hafen, 2000). 
 
How is growth coordinated in a multicelluar organism? It has been recently reported 
that in Drosophila the fat body, equivalent to the liver in mammals, plays an important 
role in responding to nutritional cues. In a genetic screen in Drosophila a mutation, slif 
(slim fast) was identified as affecting cell growth (Colombani et al., 2003). Slif encodes 
an amino acid transporter and loss-of-function slif mutant flies exhibited a phenotype 
that is similar to amino acid starved flies. Downregulation of slif specifically in the fat 
body resulted in the reduction of the larvae size suggesting that amino acid deprivation 
in the fat body alone affects growth of all larval tissues. Therefore, amino acid 
availability sensed in the fat body appears to trigger a response, which coordinates 
growth in all different tissues. TOR has been implicated to participate in the amino acid 
sensing mechanism in the fat body as inhibition of TOR resulted in phenotypes that are 
similar to those induced by downregulation of slif. In contrast, the PI3K signaling 
pathway was not involved in the amino acid sensing in the fat body. However, PI3K 
activity was inhibited in peripheral tissues in response to activation of the amino acid 
sensor mechanism in the fat body triggered by loss of slif function or inhibition of the 
TOR pathway in the fat body. How the fat body signals to other tissues is not known. 
Thus, nutritional conditions sensed in the fat body appear to trigger a humoral signal 
that regulates global growth of an organism. Since TOR is involved in the amino acid 
sensing mechanism in the fat body TOR does not only control cell-autonomous growth 
but also participates in the systemic growth control. 
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1. 4. TOR signaling in Saccharomyces cerevisiae 
 
Similar to TOR signaling in higher eukaryotes, the two TOR proteins in yeast, TOR1 
and TOR2 regulate cell growth in response to nutrients. Evidence that TOR in yeast 
integrates nutrient-derived signals will be discussed in this section. 
 
 
TOR has two functions 
Disruption of TOR1 and TOR2 individually or in combination results in different 
phenotypes. TOR1 disruption results in a slightly reduced growth rate at normal 
temperature but is lethal at high temperature (39°C) and sensitive to salt (Crespo et al., 
2001; Heitman et al., 1991a; Helliwell et al., 1994; Kunz et al., 1993). In contrast, 
depletion of TOR2 is lethal. Cells lacking TOR2 undergo a few cell divisions before 
arresting randomly in the cell cycle (Helliwell et al., 1998a; Kunz et al., 1993). The 
lethality of a TOR2 disruption cannot be suppressed by overexpression of TOR1. Cells 
lacking both TOR1 and TOR2 exhibit G1 cell cycle arrest like rapamycin-treated cells. 
These observations lead to the suggestion that TOR performs two functions. TOR1 and 
TOR2 perform a redundant, rapamycin-sensitive function in G1 progression, and in 
addition, TOR2 has an essential, unique function that TOR1 cannot perform. This 
unique function of TOR2 appears to be insensitive to rapamycin since rapamycin 
resistant TOR1 mutant alleles can support growth in the presence of rapamycin 
(Helliwell et al., 1998a; Kunz et al., 1993; Zheng et al., 1995). The functional difference 
between TOR1 and TOR2 was suggested to involve the HEAT repeats as the HEAT 
repeats of TOR1 and TOR2 are not interchangeable, whereas the catalytic domains of 
TOR1 and TOR2 are interchangeable (Helliwell et al., 1994).   
 
Below, the two TOR signaling branches in yeast are discussed. The rapamycin-
sensitive signaling branch accounts for the temporal control of cell growth, whereas the 
TOR2-unique signaling is rapamycin-insensitive and responsible for spatial control of 
cell growth. Within this thesis (Part 2) we show that these two signaling branches are 
controlled by two distinct TOR complexes. While TOR complex 1 (TORC1) mediates 
temporal control of cell growth via the rapamycin-sensitive branch, spatial control of cell 
growth is mediated by TOR complex 2 (TORC2) (Loewith et al., 2002) (illustrated in 
Fig. 1.3.). 
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1. 4. 1. Temporal control of cell growth 
 
Growth of S. cerevisiae cells is temporally controlled. Synthesis of macromolecules 
occurs when nutrients are available. TOR signaling links nutrient availability to 
macromolecular synthesis and therefore mediates temporal control of cell growth. TOR 
positively regulates anabolic processes such as translation initiation, ribosome 
biogenesis and negatively regulates catabolic processes such as RNA degradation, 
autophagy and other degradative pathways (Schmelzle and Hall, 2000). Thus, TOR 
signaling ensures that under good nutrient conditions a high rate of translation is 
maintained, whereas under poor nutrients conditions cell growth arrests. 
 
 
Readouts of the rapamycin-sensitive TOR signaling branch 
 
Translation initiation 
Rapamycin treatment or TOR depletion causes a severe decrease in translation 
initiation and an arrest in the early G1 phase of the cell cycle (Barbet et al., 1996). The 
G1 arrest observed upon rapamycin treatment appeared to be a consequence of the 
translation defect since cap-independent translation of the G1 cyclin CLN3 suppresses 
the rapamycin-induced G1 arrest. TOR1 and TOR2 seem to activate translation 
initiation via the initiation factor eIF4E, the cap-binding subunit of the heterotrimeric 
initiation factor 4F (eIF4F) (Barbet et al., 1996; Danaie et al., 1999). Similar to the 
regulation of cap-dependent translation in mammals EAP1 blocks cap-dependent 
translation via competition with eIF4G thereby inhibiting recruitment of eIF4G to eIF4E. 
In addition, disruption of EAP1 confers partial resistance to rapamycin underscoring a 
role for EAP1 in TOR signaling (Cosentino et al., 2000).  
 
TOR also regulates translation initiation through GCN2 (Cherkasova and Hinnebusch, 
2003). In starved cells GCN2 is active and phosphorylates the α-subunit of translation 
initiation factor 2 (eIF2α) resulting in a reduction of general protein synthesis 
(Hinnebusch and Natarajan, 2002). However, through a specialized reinitiation 
mechanism involving short open reading frames (uORF) in the GCN4 mRNA leader, 
GCN4 is derepressed in response to starvation and eIF2α phosphorylation. GCN4 is a 
transcription factor regulating genes involved in amino acid biosynthesis. GCN2, the 
eIF2α kinase is activated by uncharged tRNAs that accumulate during amino acid 
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starvation and bind to a histidyl-tRNA synthetase-related (HisRS) domain in GCN2. 
Under favourable growth conditions kinase activation is prevented by intramolecular 
interactions between the kinase domain and the HisRS domain of GCN2. Activation of 
GCN2 requires release of the autoinhibitory structure by tRNA leading to 
autophosphorylation of the kinase (Hinnebusch and Natarajan, 2002). It has been 
recently reported that TOR controls phosphorylation of Ser577, a phosphorylation site 
that is affecting the activity of GCN2 (Cherkasova and Hinnebusch, 2003). Inactivation 
of TOR by rapamycin results in the dephosphorylation and activation of GCN2 leading 
to downregulation of general translation and activation of GCN4. 
 
 
Ribosome biogenesis 
Ribosome biogenesis is a highly energy-demanding process and therefore has to be 
regulated according to the growth conditions and availability of nutrients (Warner, 
1999). TOR controls ribosome biogenesis at both a transcriptional and a translational 
level (Powers and Walter, 1999). Inhibition of TOR by rapamycin or nutrient starvation 
results in a downregulation of RNAII-dependent transcription of ribosome protein genes 
as well as transcription of rRNA and tRNA by polymerase I and polymerase III. In 
addition, TOR also regulates processing of the 35S precursor rRNA. 
  
 
Protein traffic and degradation 
Yeast cells can use a variety of compounds as nitrogen or carbon sources. Transport 
of these nutrients across the cell membrane is essential for cell growth and viability. 
Amino acids are essential for cell growth since they constitute the building blocks for 
protein synthesis. Yeast contain two classes of amino acid permeases which are 
regulated according to the available nitrogen source (Sophianopoulou and Diallinas, 
1995). One class consists of the low affinity, broad specificity permeases, including the 
general amino permease GAP1. The other class contains high affinity, amino acid 
specific permeases, such as the tryptophan transporter TAT2. These two classes of 
permeases are regulated in an inverse manner: under starvation conditions GAP1 is 
upregulated and routed to the plasma membrane, while specific permeases like TAT2 
are degraded. TOR has been implicated in the turnover of amino acid permease as 
inhibition of TOR by rapamycin or nitrogen starvation leads to ubiquitinylation, vacuolar 
sorting and degradation of TAT2 (Schmidt et al., 1998). TOR controls the stability of 
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TAT2 via the protein kinase NPR1. NPR1 is a phosphoprotein whose phosphorylation 
is regulated in a TOR-dependent manner. Under favourable conditions TOR keeps 
NPR1 in a highly phosphorylated and inactive state. Upon TOR inhibition by rapamycin 
or nitrogen starvation NPR1 is rapidly dephosphorylated and activated. Active NPR1 
leads to the subsequent ubiquitinylation and degradation of TAT2 (Schmidt et al., 
1998). However, the substrate of NPR1 is not known. On the other hand, TOR 
regulates GAP1 inversely to TAT2. Upon TOR inactivation by rapamycin GAP1 is 
transcriptionally upregulated (Beck and Hall, 1999). GAP1 is also posttranslationally 
controlled by NPR1 as NPR1 is required for sorting to and stabilization of GAP1 at the 
plasma membrane under starvation conditions (De Craene et al., 2001; Vandenbol et 
al., 1990). It was proposed that TOR may negatively control sorting of GAP1 by 
keeping NPR1 in its phosphorylated and inactive state (Beck et al., 1999). 
 
 
Autophagy 
When starved yeast cells degrade their cytosol and organelles to ensure survival under 
these unfavourable growth conditions. This catabolic process is mediated by 
autophagy involving the enclosure of cytoplasm by a double membrane structure 
(autophagosome) and the subsequent delivery to the vacuole (Klionsky and Ohsumi, 
1999). TOR has been implicated in autophagy as inhibition of TOR by rapamycin 
induces autophagy (Noda and Ohsumi, 1998). TOR controls autophagy via APG13 
(Kamada et al., 2000). APG13 forms a complex with the protein kinase APG1 and 
formation of APG13-APG1 complex is required for autophagy. Under good nutrient 
conditions TOR maintains APG13 in a hyperphosphorylated form preventing the 
association with APG1 and thereby also autophagy. Starvation or treatment with 
rapamycin leads to a dephosphorylation of APG13, association of APG1 with APG13 
and induction of autophagy. 
 
 
Transcription 
TOR positively and negatively regulates transcription. Under favourable nutrient 
conditions TOR activates transcription of ribosomal protein, rRNA and tRNA genes 
(Powers and Walter, 1999). TOR also inhibits transcription of many nutrient or stress-
regulated genes mainly by maintaining several nutrient and stress-responsive 
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transcription factors in the cytoplasm (Beck and Hall, 1999; Cardenas et al., 1999; 
Hardwick et al., 1999; Komeili et al., 2000). 
 
GATA transcription factors GLN3 and GAT1 
GLN3 and GAT1 control genes which are involved in the uptake and the assimilation of 
alternative nitrogen sources (Magasanik and Kaiser, 2002). GLN3 and GAT1 reside in 
the cytoplasm in cells, which are grown in the presence of a good nitrogen source 
(glutamine, glutamate or ammonia). Upon shift to a poor nitrogen source (urea or 
proline) or upon TOR inactivation by rapamycin, GLN3 and its cytoplasmic anchor 
URE2 are dephosphorylated resulting in a dissociation of GLN3 from URE2. 
Subsequently, GLN3 translocates to the nucleus and induces the expression of its 
target genes (Beck and Hall, 1999).  
 
RTG1 and RTG3 
RTG1 and RTG3 regulate expression of tricarboxylic acid and glyoxylate cycle genes. 
Expression of these genes primarily leads to the synthesis of α-ketoglutarate, which is 
required for the de novo synthesis of amino acids such as glutamate and glutamine. 
Nitrogen starvation or inhibition of TOR by rapamycin leads to the nuclear translocation 
of RTG1/3 and the activation of their target genes (Komeili et al., 2000). TOR 
negatively controls the activity of RTG1 and RTG3 through the regulatory proteins 
RTG2 and MKS1 (Dilova et al., 2002; Liu et al., 2003). 
 
Zn-finger transcription factor MSN2 and MSN4 
MSN2 and MSN4 are redundant transcription factors which activate a large number of 
genes in response to many types of stress including carbon starvation (Gorner et al., 
1998; Smith et al., 1998). Additionally, MSN2/4 are negatively controlled by TOR. 
Under optimal growth conditions MSN2/4 are associated with the 14-3-3 proteins 
BHM1 and BMH2 and localized in the cytoplasm. Upon carbon-starvation or rapamycin 
treatment MSN2/4 are released from BMH1/2 and translocate to the nucleus (Beck and 
Hall, 1999). 
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Effector pathways of the rapamycin-sensitive TOR signaling branch 
 
The TOR effector pathways of the rapamycin-sensitive signaling branch, which 
mediates the temporal control of cell growth, are not known in all cases. Some of the 
readouts of the rapamycin-sensitive signaling branch involve the negative regulation of 
type 2A phosphatases by TOR. 
 
 
TOR regulates protein phosphatases 
Type 2A phosphatases (PP2A) are composed of a catalytic (C) and two regulatory 
subunits (A and B). While the catalytic subunit is broadly active the regulatory subunits 
determine the specificity towards a target protein as well as the subcellular localization 
of the phosphatase complex (Goldberg, 1999). The PPH21 and PPH22 catalytic 
subunits associate with the regulatory A subunit, TPD3, and one of two B subunits, 
CDC55 or RTS1 (Zabrocki et al., 2002). The PP2A-related phosphatase is composed 
of the catalytic subunit SIT4 which associates with one of four regulatory proteins, 
SAP4, SAP155, SAP185, SAP190 (Luke et al., 1996). TOR negatively controls SIT4 
and PP2A by promoting the association of the catalytic subunits PPH21/22 and SIT4 to 
TAP42 (Di Como and Arndt, 1996). Binding of the catalytic subunits to TAP42 prevents 
the association of the catalytic subunits with regulatory subunits leading to the inhibition 
of SIT4 and PP2A. TOR might regulate the association of TAP42 with PPH21/22 by 
phosphorylation of TAP42 (Jiang and Broach, 1999), whereas the binding of TAP42 to 
SIT4 seems to be indirectly controlled by TOR through the TAP42-interacting protein 
TIP41 (Jacinto et al., 2001). TOR maintains TIP41 in a phosphorylated form and 
thereby promotes the binding of TAP42 to SIT4. Upon TOR inactivation by rapamycin 
or under starvation conditions TIP41 is dephosphorylated and binds TAP42. As a 
consequence SIT4 is released from TAP42 and is activated. Activated SIT4 is able to 
dephosphorylate more TIP41 resulting in the amplification of the phosphatase activity.  
 
TOR controls several readouts via the TAP42-SIT4 effector pathway. The 
phosphorylation status and therefore also the activity of the transcription factors GLN3 
and GAT1, the protein kinase NPR1 and eIF2α kinase GCN2 are regulated in a SIT4-
dependent manner (Loewith and Hall, 2004). 
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TOR and RAS signaling pathway 
Similar to the TOR pathway the RAS/cyclic AMP (cAMP) pathway plays a major role in 
the control of growth in response to nutrients. The RAS signaling pathway consists of 
two redundant small GTPases RAS1 and RAS2 (RAS), which are activated by the 
guanine nucleotide exchange factor CDC25. In its activated state RAS activates 
adenylate cyclase (encoded by CDC35) leading to the production of cAMP. Protein 
kinase A (PKA) is composed of a catalytic subunit (redundantly encoded by TPK1, 
TPK2 and TPK3) and the regulatory subunit (encoded by BCY1). cAMP causes a 
release of TPK from BCY1 which activates the kinase. Similar to nutrient-depleted 
cells, inactivation of PKA causes a cell cycle arrest in G1, an accumulation of storage 
carbohydrates (glycogen and trehalose) and a downregulation of ribosome biogenesis. 
Downstream targets of PKA include enzymes involved in intermediary carbon 
metabolism, the transcription factors MSN2 and MSN4 and RIM15, a protein kinase 
involved in stationary phase induction (Thevelein and de Winde, 1999). 
 
Recently, the RAS/cAMP signaling pathway have been proposed to act as an effector 
pathway of the TOR signaling pathway (Schmelzle et al., 2004). It has been shown that 
activation of the RAS/cAMP pathway renders cells resistant to rapamycin-induced, 
SIT4-independent processes, such as nuclear translocation of MSN2, accumulation of 
glycogen, and downregulation of ribosome biogenesis. On the other hand, activation of 
the RAS/cAMP pathway did not affect rapamycin-induced processes regulated by 
SIT4, like the nuclear transport of GLN3 and the phosphorylation of NPR1. Thus, TOR 
appears to control rapamycin-sensitive readouts that are independent of SIT4 through 
the RAS/cAMP pathway. TOR may control the RAS/cAMP pathway via regulating the 
localization of the PKA catalytic subunits as TOR inactivation by rapamycin leads to the 
nuclear translocation and presumably inactivation of TPK1. However, the mechanism 
by which TOR regulates the RAS/cAMP pathway remains unclear as it has been also 
suggested that MSN2 is controlled in parallel by TOR and the RAS/cAMP pathway 
(Gorner et al., 1998; Gorner et al., 2002).  
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1. 4. 2. Spatial control of cell growth 
 
TOR does not only mediate the temporal control of cell growth but also the spatial 
control of cell growth. Growth of a daughter cell in yeast occurs at a discrete site (the 
bud site) on the surface of a mother cell. TOR2 regulates spatial control of cell growth 
via the organization of the actin cytoskeleton. Polarization of the actin cytoskeleton 
orients the secretory pathway to the bud and therefore ensures that newly synthesized 
proteins and other cellular constituents are targeted to the growth site. 
 
 
Organization of the actin cytoskeleton 
In yeast cells growth is polarized, occurring at a defined position at the cell surface. 
The structural basis for cell polarity is provided by the actin cytoskeleton. The yeast 
actin cytoskeleton is organized into at least three morphologically distinct structures: 
cortical patches, actin cables and a cytokinetic ring. Cortical patches are discrete 
cytoskeletal bodies whereas actin cables are long bundles of actin filaments. The 
distribution of actin patches and cables is polarized in a cell-cycle dependent manner. 
The polarity is established by actin cables forming a network that polarizes the cell 
towards the bud. Cortical patches are thought to maintain polarity by recycling 
components such as enzymes necessary for cell wall synthesis ensuring a proper cell 
wall assembly when growth is redirected through the cell cycle. The function of the 
actin cytoskeleton is to provide cell polarity that guides a variety of events, such as 
transport of vesicles from the Golgi and endosomal elements from the mother cell into 
the bud, organelle movement and positioning, mRNA anchorage, endocytosis and 
mitotic spindle orientation (Pruyne and Bretscher, 2000a; Pruyne and Bretscher, 
2000b). The actin cytoskeleton is also required to respond to environmental signals. 
The organization of the actin cytoskeleton is altered in response to nutrient availability, 
pheromone or change in osmolarity or temperature (Beck et al., 2001). 
 
The actin cytoskeleton is organized in a cell cycle dependent manner. During early G1 
actin cables and patches are randomly distributed in the cytoplasm whereas late in G1 
when the cell initiates a new cell cycle the actin cytoskeleton polarizes. Actin patches 
concentrate at the preselected bud site and actin cables orients towards the bud site. 
During bud emergence and maturation actin patches are located in the bud while actin 
cables orient from the mother cells into the bud of the daughter cell. At the end of bud 
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growth the polarization is lost and the actin patches and cable redistribute randomly in 
the mother and daughter cell. Prior to cytokinesis a ring consisting of F-actin is 
assembled at the bud neck, then contracts and disassembles after mitosis. Following 
cytokinesis the actin cytoskeleton is repolarized. Actin patches concentrate at the bud 
neck while actin cables orient towards the bud neck directing synthesis of new cell 
walls. The cell-cycle dependent polarization of the actin cytoskeleton is established by 
RHO-type GTPases (Beck et al., 2001; Schmidt and Hall, 1998). 
 
 
RHO-GTPases 
RHO-GTPases play a pivotal role in the organization of the actin cytoskeleton not only 
in S. cerevisiae but also in higher eukaryotes (Etienne-Manneville and Hall, 2002). Like 
all small G-proteins, RHO-GTPases cycle between an active, GTP-bound, and an 
inactive, GDP-bound, conformation. In its GTP-bound form the GTPase is able to 
recognize target proteins and thereby exert a signaling response.  Active GTPase 
returns to its inactive state through hydrolysis of GTP. The cycle between GTP-bound 
and GDP-bound form is regulated by three classes of proteins: GEFs (guanine 
nucleotide exchange factors), GAPs (GTPase-activating proteins) and GDIs (guanine 
nucleotide exchange inhibitors). The GEFs activate the GTPase by catalyzing the 
nucleotide exchange whereas the GAPs stimulate the hydrolysis of GTP leading to the 
inactivation of the GTPase. 
 
There are six RHO-GTPases in S. cerevisiae, CDC42, RHO1, RHO2, RHO3, RHO4 
and RHO5 (Chant, 1999). CDC42 plays a central role in controlling the polarization of 
the yeast cell during budding and mating. RHO1 and RHO2 are important for 
maintenance of the actin cytoskeleton polarization and cell wall activities during bud 
growth. Bud growth is also controlled by RHO3 and RHO4. 
 
 
TOR2 controls the organization of the actin cytoskeleton 
Cells disrupted for TOR2 exhibit a defect in the organization of the actin cytoskeleton 
and it has been reported that TOR2 signals to the actin cytoskeleton through activation 
of the small GTPase RHO1 (Schmidt et al., 1997; Schmidt et al., 1996). Deletion of 
SAC7, a GAP for RHO1, suppresses the growth defect of a tor2 mutant but not of a 
tor1 tor2 double mutant indicating that deletion of SAC7 only suppresses a defect in the 
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signaling branch that is specifically controlled by TOR2. Conversely, overexpression of 
ROM2, a GEF for RHO1, or overexpression of the small GTPases RHO1 and RHO2 
are able to restore the growth defect of tor2 mutant cells. TOR2 appears to regulate the 
GTPase switch via ROM2 as the GDP/GTP exchange activity of ROM2 toward RHO1 
is drastically reduced in a tor2 mutant (Schmidt et al., 1997). Thus, TOR2 activates 
RHO1 and RHO2 but the mechanism by which TOR2 controls the activity of ROM2 is 
not known. 
 
Activated RHO1 in turn regulates different effectors including PKC1, the 1,3-β-glucan 
synthase FKS1 and FKS2, the formin-family protein BNI1, the two-component signaling 
protein SKN7, and SEC7, a spatial landmark for exocytosis (Alberts et al., 1998; Guo et 
al., 2001; Schmidt and Hall, 1998). Suppressor studies in tor2 mutant strains using 
different RHO1 effectors indicated that TOR2 signals to the actin cytoskeleton via the 
RHO1 effector PKC1 (Helliwell et al., 1998b). PKC1 controls a mitogen-activated 
protein kinase (MAPK) cascade comprising BCK1 (MEKK), the redundant MKK1 and 
MKK2 (MEK), and MPK1 (MAPK). Activation of the pathway leads to the upregulation 
of genes that are involved in cell wall biogenesis (Heinisch et al., 1999). Further the 
PKC1-MAP kinase pathway have been implicated in the organization of the actin 
cytoskeleton (Helliwell et al., 1998b). First, rho1 mutant cells display an actin defect 
that is suppressed by overexpression of PKC1. Second, overexpression of components 
of the PKC1-MAP kinase cascade restored the actin defect of tor2 mutant cells. Thus, 
by controlling cell wall biosynthesis and the actin cytoskeleton the RHO1-PKC1-MAP 
kinase pathway maintains cell shape and integrity and is therefore also referred as cell 
integrity pathway. The cell integrity pathway is controlled by a variety of signaling 
events including cell wall sensing mechanisms via WSC1 and MID2, lipid signaling 
mediated by MSS4, and actin depolarization (Audhya and Emr, 2002; Harrison et al., 
2001; Heinisch et al., 1999). It has to be noted that the PKC1-MAP kinase pathway is 
required for entry of starved cells into stationary phase and viability in G0, a process 
that includes remodelling of the cell wall and that is also controlled by the rapamycin-
sensitive TOR signaling branch (Krause and Gray, 2002; Torres et al., 2002).  
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1. 4. 3. TOR controls cell growth in response to nutrients 
 
Several lines of evidence indicate that TOR controls cell growth in response to 
nutrients. First evidence that TOR may respond to nutrients came from the observation 
that inactivation of TOR by rapamycin results in an early G1 arrest, reduced protein 
synthesis and accumulation storage carbohydrates (glycogen), a phenotype 
characteristic for starved cells. Thus, inactivation of TOR appears to induce a 
starvation response (Barbet et al., 1996). The role of TOR in nutrient sensing was 
further supported by the findings that TOR controls autophagy, ribosome biogenesis as 
well as the activity of amino acid permeases via NPR1, all of which are regulated in 
response to nutrients (Noda and Ohsumi, 1998; Powers and Walter, 1999; Schmidt et 
al., 1998). Analysis of the genome-wide transcription program in rapamycin treated 
cells revealed that TOR controls transcription of nutrient-regulated genes (Cardenas et 
al., 1999; Hardwick et al., 1999). TOR regulates these genes through several 
transcription factors, including GLN3, GAT1, RTG1/RTG3 and MSN2/MSN4 (Beck and 
Hall, 1999; Komeili et al., 2000). Since GLN3, GAT1 and RTG1/RTG3 are regulated in 
response to the nitrogen source and MSN2/MSN4 in response to the carbon source it 
has been proposed that TOR signaling might respond to nitrogen and possibly carbon. 
How might TOR sense these nutrients? In particular the nitrogen source appears to 
play an important role in the TOR signaling as genes required for the import and 
metabolism of alternative nitrogen sources are strongly upregulated upon rapamycin 
treatment (Cardenas et al., 1999; Hardwick et al., 1999; Shamji et al., 2000). Yeast 
cells can use a variety of nitrogen sources. In order to use a compound as nitrogen 
source yeast cells have to convert this compound into glutamate or glutamine which 
serve as nitrogen donors. α-ketoglutarate derived from the TCA cycle is the precursor 
for glutamate while glutamine, the preferred nitrogen source, is synthesized out of 
ammonium and glutamate by glutamine synthetase (GS), encoded by GLN1(ter Schure 
et al., 2000). It has been reported that glutamine controls a subset of TOR-regulated 
readouts (Crespo et al., 2002). Chemical inhibition of GS leads to the depletion of 
glutamine and results in the activation of the TOR-controlled transcription factors 
GLN3, RTG1 and RTG3, whereas other TOR-regulated transcription factors, GAT1, 
MSN2, MSN4 and expression of ribosomal genes are not affected by glutamine levels. 
It was proposed that TOR might sense a variety of nutrients and accordingly trigger 
different responses (Kuruvilla et al., 2001; Shamji et al., 2000). Glutamine might be one 
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of these nutrients serving as an indicator of the nutritional status of a cell.  How TOR 
senses glutamine or other nutrients remains unknown. 
 
The TOR signaling pathway has been recently linked to the RAS/cAMP pathway 
underscoring a role of TOR in control of cell growth in response to nutrients (Schmelzle 
et al., 2004). Similar to the TOR signaling pathway the RAS/cAMP pathway is 
controlled by nutrient availability. While TOR is likely regulated in response to nitrogen, 
the RAS/cAMP pathway is controlled in particular by the presence of glucose which is 
sensed by G-protein-coupled receptor system consisting of GPR1 and its Gα protein 
GPA2 (Thevelein and de Winde, 1999). It was therefore suggested the RAS/cAMP 
pathway is controlled by different inputs: TOR may mediate the nitrogen-responsive 
input, whereas the glucose-responsive input is sensed by the GPR1/GPR2 system. 
 
Thus, similar to TOR in higher eukaryotes TOR in yeast controls cell growth in 
response to nutrients, but the mechanism by which nutrient levels or the quality of 
nutrients are sensed by TOR is not understood. Unlike higher organisms where TOR is 
controlled in addition to nutrients by growth factors, yeast cells lack a growth factor 
signaling pathway. It is thought that the TOR signaling pathway may represent an 
ancestral pathway developed in unicellular organisms that controls cell-autonomous 
growth in response to nutrients; the growth factor signaling pathway evolved in higher 
eukaryotes impinges on TOR to coordinate growth of different tissues (Jacinto and 
Hall, 2003).  
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2. Identification of TOR complexes 
 
TOR controls two signaling branches that can be genetically and functionally 
discriminated. TOR1 and TOR2 redundantly regulate translation, transcription and 
ribosome biogenesis in a rapamycin-sensitive fashion. TOR2 but not TOR1 regulates 
polarization of the actin cytoskeleton in a rapamycin-insensitive fashion. How specificity 
is achieved in the TOR signaling network was not understood. Since TOR is composed 
of multiple domains such as the HEAT repeats which could serve as potential protein-
protein interaction domains it was speculated that TOR might interact with other, so far 
unknown proteins. The biochemical purification of both TOR1 and TOR2 presented in 
the following article lead to the identification of two structurally and functionally distinct 
TOR complexes which account for the specificity of TOR signaling. My contribution to 
this work was the characterization of AVO1.  
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2. 2. Additional results 
 
AVO1 is not required for the rapamycin-sensitive TOR-sensitive function 
Previously, we showed that AVO1 is required for the rapamycin-insensitive TOR2-
unique signaling branch, the organization of the actin cytoskeleton. To test whether 
AVO1 is only involved in the TOR2-unique function, the effect of AVO1 depletion on the 
rapamycin-sensitive TOR signaling branch was examined. TOR controls the 
phosphorylation status and thereby the activity of NPR1 (Schmidt et al., 1998). Under 
favourable nutrient conditions TOR maintains NPR1 in a highly phosphorylated and 
inactive state. Upon TOR inactivation by rapamycin treatment NPR1 is 
dephosphorylated by SIT4 and activated. To check the effect of AVO1 on NPR1 
phosphorylation AVO1 was put under the control of a galactose-inducible and glucose-
repressible promoter and the phosphorylation status of NPR1 was detected by gel 
mobility shift. NPR1 phosphorylation was similar in wild-type cells or cells 
overexpressing AVO1 (Fig. 2.1; compare lane 1, 2 to lane 5, 6). NPR1 phosphorylation 
was similarly unaltered by depletion of AVO1 (Fig. 2.1.; compare lane 3, 4 to lane 7, 8). 
As in wild-type cells, NPR1 was phosphorylated under favourable growth conditions 
and dephosphorylated upon treatment with rapamycin. Thus, AVO1 is not required for 
the regulation of NPR1 suggesting that AVO1 does not play a role in the rapamycin-
sensitive TOR signaling branch.  
 
 
 
 
 
 
 
 
 
Figure 2.1. AVO1 does not affect the phosphorylation status of NPR1 
Wild-type (TB50a) or GAL1 promoter-AVO1 (RL23-1c) strains carrying HA-NPR1 (pEJ23, YEplac181::HA-
NPR1) were grown for 15 hr in either SGal/Gly-leu or SD-leu medium to log phase at 30°C and then either 
treated for 10 min with 100 ng/ml rapamycin or drug vehicle (90% ethanol, 10% Tween-20). Cells were 
harvested and lysed. Total cellular extracts (30 µg total protein) were fractionated on 7.5% SDS-PAGE, 
transferred to nitrocellulose, and probed with anti-HA antibody. 
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Is AVO1 a conserved protein? 
The components of the rapamycin-sensitive TORC1, KOG1 and LST8 are highly 
conserved from yeast to flies to humans. Similar to TOR1 and TOR2 in yeast, mTOR 
forms a complex with raptor (KOG1 in yeast) and mLST8 (Hara et al., 2002; Kim et al., 
2002; Loewith et al., 2002). Raptor and mLST8 seem to be important for the 
rapamycin-sensitive functions of mTOR, such as phosphorylation of 4E-BP1 and 
p70S6K. The components of the rapamycin-insensitive TORC2 do not have strong 
homologues in higher organisms. AVO1 displays a similarity to hSIN1, a human protein 
that was identified as a RAS suppressor in yeast (Colicelli et al., 1991). The overall 
identity of the two proteins is 19%. The two proteins are most similar in the C-terminus 
of AVO1, whereas the N-terminus of AVO1 is not conserved. hSIN1 exhibits a much 
smaller molecular weight (58kDa) compared to AVO1 (130kDa). Tissue blot analysis 
revealed that the expression level of hSIN1 was similar to that of mTOR (Loewith et al., 
2002). Both are highly expressed in muscle, heart, liver and kidney. To test a possible 
interaction between hSIN1 and mTOR, recombinant, tagged hSIN1 and mTOR were 
transfected into HEK-239 cells to perform coimmunoprecipitations. Myc- tagged hSIN1 
did not precipitate with HA- tagged mTOR in HEK-239 cells (data not shown). In 
collaboration with the group of Markus Rüegg (Biozentrum, Basel) a polyclonal 
antibody against hSIN1 was raised to check whether endogenous, untagged hSIN1 
could interact with mTOR. However, endogenous hSIN1 was not able to interact with 
mTOR by coimmunoprecipitation in HEK-239 leading to the conclusion that hSIN1 
does not interact with mTOR under the conditions we tested.  
 
 
 
2. 3. Discussion 
 
The additional data underscore the existence of two structurally and functionally distinct 
TOR complexes in yeast. AVO1, a member of TORC2 appears to be only required for 
the TOR2-unique signaling branch and did not affect the rapamycin-sensitive TOR 
signaling branch such as the phosphorylation status of NPR1 nor the expression of 
GLN3 and RTG1/3 target genes (Loewith et al., 2002). 
 
Whether AVO1 is a conserved protein is unclear. We failed to detect an interaction 
between the putative AVO1 homologue hSIN1 and mTOR by coimmunoprecipitation. 
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However, there is evidence that some protein-protein interactions of TORC in 
mammalian cells are rather unstable and very sensitive to detergents (Hara et al., 
2002; Kim et al., 2002). It is possible that our conditions are not suited to detect an 
association between hSIN1 and mTOR. It is also possible that the interaction between 
hSIN1 and mTOR is dependent on the cell type. Different TOR complexes could be 
formed depending on the function of mTOR in various tissues.  
 
Nevertheless, it has been recently found, that there is a homologue of AVO3 in 
mammalian cells indicating the existence of different and possibly rapamycin-
insensitive TOR complexes in mammalian cells which might also be important for the 
organization of the actin cytoskeleton (R. Loewith, E. Jacinto unpublished data). 
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3. Characterization of AVO1 and LST8 
 
3. 1. Introduction 
 
In yeast TOR exists in two complexes, TOR complex 1 (TORC1) and TOR complex 2 
(TORC2) as shown in the first part of this thesis. These two complexes, which contain 
both common and distinct proteins, account for the specificity of TOR signaling. 
TORC1 mediates the rapamycin-sensitive signaling branch, which regulates 
transcription, translation and ribosome biogenesis. TORC2 signaling is rapamycin-
insensitive and is required for the organization of the actin cytoskeleton. How TORC2 
controls the organization of the actin cytoskeleton is not completely known. As 
introduced in the general introduction (Part 1), TOR2 is thought to regulate actin via the 
control of the RHO1 GTPase switch (Helliwell et al., 1998b; Schmidt et al., 1997). Upon 
activation of RHO1 by its exchange factor ROM2, activated RHO1 interacts with, and 
activates PKC1. Activated PKC1 subsequently signals to actin by activation the MAP 
kinase cascade consisting of BCK1, MKK1/2 and MPK1. 
 
The yeast protein kinases YPK1 and YPK2, an essential pair of homologous kinases 
have been linked to the PKC1-controlled MAP kinase cascade (Schmelzle et al., 2002). 
YPKs are phosphorylated and thereby activated by the kinase pair PKH1 and PKH2 
(Casamayor et al., 1999). Apart from regulating the YPKs, the PKHs also activate 
PKC1 through direct phosphorylation (Inagaki et al., 1999). The PKH - YPK signaling 
pathway is suggested to act downstream of a sphingolipid-derived signal (Sun et al., 
2000). 
 
The PKHs are the yeast orthologues of the mammalian phosphoinositide-dependent 
kinase (PDK1). Mitogenically activated PDK1 has been reported to phosphorylate a 
conserved residue in the activation loop of several members of the AGC kinases 
(cAMP-dependent protein kinase (PKA), protein kinase G (PKG), protein kinase C 
(PKC)) (Vanhaesebroeck and Alessi, 2000). Among other AGC kinases PDK1 
activates p70S6K and serum- and glucocorticoid-induced kinase (SGK), the 
mammalian homologue of YPK1 and YPK2 indicating that the PKH-YPK pathway is 
conserved (Alessi et al., 1998; Park et al., 1999). 
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Here we study the role two TORC2 proteins AVO1 and LST8, mainly focusing on 
AVO1. Analyzing avo1 and lst8 mutants we confirm their positive function with TOR2 in 
the regulation of the actin cytoskeleton. 
 
 
3. 2. Results 
 
Growth and actin defects of avo1 and lst8 mutants are suppressed by activation 
of the RHO1-GTPase switch or the PKC1 MAP kinase cascade 
Previously, we have reported that activation of the RHO1 GTPase switch by 
overexpression of a RHO1 GEF ROM2, the RHO1-related GTPase RHO2, or activated 
alleles of PKC1, BCK1 or MKK1 restored the viability of an avo1 mutant strain (Loewith 
et al., 2002). We also found that deletion of SAC7, encoding a GAP for RHO1, 
suppressed the growth defect of avo1 (data not shown). We did not observe any 
suppression of avo1 mutants by overexpression of the TOR2-suppressors SUR1 or 
PLC1 nor by overexpression of other RHO1 effectors FKS1, encoding glucan synthase, 
BNI1, encoding the yeast formin or SKN7 (data not shown). Interestingly, 
overexpression of YPK2, encoding a kinase that has been previously implicated in the 
cell integrity pathway restored the growth defect of avo1 cells (data not shown). Since 
YPK2 is phosphorylated and activated by the PKH1 and PKH2 protein kinases, which 
have also been linked to PKC1, we tested whether overexpression of the PKHs could 
rescue an avo1 mutant. Overexpression of PHKs did not suppress avo1, possibly 
because the kinases are not in their activated state (data not shown).  
 
To study the essential role of LST8 a conditional LST8 mutant strain was created 
replacing the original LST8 promoter with a glucose-repressible and galactose-
inducible GAL1 promoter. Because tor2 and avo1 mutant cells are suppressed by 
activation of the RHO1 GTPase switch or by hyperactivation of the PKC1 effector MAP 
kinase pathway, we tested whether overexpression of components in these pathways 
were also able to suppress an lst8 mutant. Activation of the RHO1 GTPase switch by 
overexpression of ROM2 or RHO2 did not restore the growth defect of lst8 mutant 
cells, whereas mutation of SAC7 weakly suppressed the lethality of an lst8 mutant (Fig. 
3.1. and data not shown). Additionally, overexpression of MSS4 that encodes a 
phosphatidylinositol kinase, and is a strong suppressor of tor2 and avo1 did not rescue 
the lst8 mutant. As shown in Fig. 3.1. activation of the PKC1-MAP kinase cell integrity 
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pathway by overexpression of PKC1, BCK1, MKK1 and constitutively activated alleles 
thereof lead to a partial suppression of the growth defect of lst8 on glucose-containing 
media. Interestingly, a weak suppression of lst8 mutant cells was observed in cells 
overexpressing TOR2, a result not observed in avo1 cells. Surprisingly, the most potent 
multicopy suppressor of lst8 was YPK2, which restored the growth of lst8 cells to 
almost wild-type level. Thus, analysis of avo1 and lst8 multicopy suppressors 
underscores the positive role of AVO1 and LST8 in TORC2. The fact that LST8 is 
present in both complexes, in the rapamycin-sensitive TORC1 and in TORC2 might 
explain why the lethality of lst8 can only be partially suppressed by known TORC2 
suppressors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Growth defect of lst8 mutant cells is suppressed by activation of the 
PKC1 MAP kinase cascade and YPK2  
Wild-type (wt) (TB50a) and GAL1 promoter-LST8 cells transformed with empty vector, pRHO2, pPKC1, 
pPKC1*, pMKK1*, pMKK1, pBCK1*, pMPK1, pTOR2, pMSS4, or pYPK2 were streaked onto SGal/Gly-ura 
(galactose) and SD-ura (glucose) plates and incubated at 30°C. 
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Since AVO1 is required for organization of the actin cytoskeleton we tested if the 
identified growth suppressors could rescue the actin defect of avo1 mutant cells. The 
distribution of the actin cytoskeleton of wild-type cells was compared to avo1 mutant 
cells containing either empty control plasmid or a multicopy suppressor plasmid. Cells 
were grown under glucose conditions leading to the depletion of AVO1, and the 
distribution of the actin cytoskeleton was visualized by phalloidin staining. Wild-type 
cells exhibited a normal distribution of the cell cycle-dependent organization of the 
actin; in small-budded cells, the actin patches are concentrated at the bud and actin 
cables are oriented in the mother cell towards to bud (Fig. 3.2.). avo1 mutant cells 
containing an empty control plasmid failed to properly localize actin as indicated by a 
random distribution of actin patches in the mother cell of small-budded cells (Fig. 3.2.). 
In avo1 cells, overexpressing a constitutively active allele of PKC1 partially restored the 
defect in the actin organization. These cells concentrated actin patches in the growth 
site, however, we did not observe actin cables in the mother cell of small-budded cells 
(Fig. 3.2.). We also looked at the actin cytoskeleton in lst8 mutant cell overexpressing 
YPK2. However, as reported earlier the actin defect of lst8 mutant cells was not as 
pronounced as in avo1 mutant cells (Loewith et al., 2002) and we failed to detect a 
significant difference between lst8 mutant cells transformed with empty plasmid or with 
pYPK2 (data not shown). The finding that activated PKC1 partially suppressed the 
actin defect of avo1 mutant cells support an involvement of AVO1 in the PKC1-MAP 
kinase pathway. 
 
 
 
 
 
 
 
 
 
Figure 3.2. Actin defect of avo1 is suppressed by activation of the PKC1 MAP 
kinase cascade.  
Wild-type (TB50a) cells and GAL1 promoter-AVO1 (RL23-1c) transformed with empty plasmid or pPKC1* 
were pregrown in SGal/Gly (galactose) medium and shifted to YPD (glucose) medium for 15 hr, fixed, 
stained for actin with TRITC-phalloidin, and observed by fluorescence (actin, top panel) and Nomarski 
(bottom panel) microscopy. 
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AVO1 is required for full activation of MPK1 in response to heat shock 
To further confirm the role of AVO1 in the cell integrity pathway we examined the 
activation of the PKC1-controlled MAP kinase MPK1 in AVO1-deficient cells. MPK1 is 
activated by various stresses, such as heat shock treatment (Heinisch et al., 1999). We 
monitored the kinetics of heat stress-induced MPK1 activation in AVO1-depleted cells. 
Activation of MPK1 was detected using an antibody that specifically recognizes the 
activated, dually phosphorylated form of MPK1. In wild-type cells, heat-induction leads 
to a transient activation of MPK1. Maximal activation was reached 30 to 60 min after 
shift from 24°C to 39°C, while MPK1 phosphorylation levels returned to basal levels 
within 120 min after the shift. This transient MPK1 activation correlates with the 
previously reported transient actin depolarization upon heat shock (Delley and Hall, 
1999). The kinetics of MPK1 activation was similar in avo1 mutant cells, but the level of 
activation was decreased compared to wild-type cells (Fig 3.3.). Total MPK1 levels, 
determined by immunoblotting were similar in wild-type and avo1 cells at all time 
points. The residual activity of MPK1 observed in avo1 could be due to incomplete 
depletion of AVO1. The finding that MPK1 activation in response to heat shock was 
reduced in AVO1-depleted cells suggests that AVO1 plays a positive role in the cell 
integrity pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. AVO1 is required for full activation of MPK1 
Wild-type (wt) (TS99-5c) and GAL1 promoter-AVO1 (SW35-5c) cells expressing HA-tagged MPK1 were 
grown for 16 hr in glucose medium at 24°C (time 0). Cells were shifted to 39°C for the indicated times (30, 
60, 90, 120 min) and activated MPK1 was detected by immunoblotting using a specific antibody that 
recognizes dually phosphorylated MPK1 (phospho-MPK1, top panel). Expression of HA-tagged MPK1 was 
analyzed by immunoblotting using anti-HA antibody (bottom panel). 
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AVO1 interactors 
TOR2 controls the actin cytoskeleton by activation of the RHO-GTPase switch via the 
GEF ROM2 (Schmidt et al., 1997). The mechanism by which TOR2 regulates the 
ROM2 exchange activity is unknown. Therefore, we tested whether TOR2 might signal 
through its partner proteins, such as AVO1, to the GEF ROM2 and thereby regulate the 
activity of the GTPases RHO1 and RHO2. To check this possibility 
coimmunoprecipitation experiments with epitope-tagged versions of AVO1 and ROM2 
were performed: we did not detect an interaction between AVO1 and ROM2 (data not 
shown). Using a yeast two-hybrid assay we examined if AVO1 interacts directly with 
the GTPase RHO1, which could possibly lead to an activation of RHO1. However, we 
failed to detect an interaction between AVO1 and the wild-type RHO1, nucleotide-free 
RHO1 (RHO1-G22A), nor activated, GTP-trapped RHO1 (RHO1-Q68H) (data not 
shown). Therefore, using these approaches we could not detect any interaction 
between AVO1 and already known components that are possibly regulated by TORC2 
to organize the actin cytoskeleton. 
 
In order to identify novel interactors of AVO1, which could link AVO1 to the 
organization of the actin cytoskeleton a large-scale purification of AVO1, was 
performed. The purification procedure relied on a TAP (tandem affinity purification)- 
tagged version of AVO1 expressed at endogenous levels. The TAP tag combines two 
different tags, an IgG binding domain of Staphylococcus aureus protein A and a 
Calmodulin binding peptide, separated by a cleavage site that is recognized by the 
TEV protease (Puig et al., 2001). Purified proteins were resolved by SDS-PAGE and 
identified by mass spectrometry. A mock purification using untagged AVO1 was also 
performed to identify proteins that specifically interact with AVO1. AVO1 copurified only 
with the previously identified components of TORC2, namely TOR2, AVO2 and AVO3. 
LST8 which is also a component of TORC2 could not be detected in the purification 
because the LST8 comigrates with a contaminating protein also found in the mock 
purification (data not shown). 
 
In an additional attempt to identify AVO1 interacting proteins a yeast two-hybrid screen 
using full-length AVO1 as bait was performed. We reasoned that a yeast two-hybrid 
screen would allow the identification of unstable or transient interactors. Such weak 
protein-protein interactions are lost in a biochemical purification procedure since it 
involves several washing steps with quite high salt concentrations. Yeast cells 
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expressing the GAL4 DNA binding domain fused to the N-terminus of full length AVO1 
was transformed with a plasmid library containing the prey fused to the GAL4 
transcriptional activation domain. After selection and isolation of positive library 
plasmids, 13 candidates were retransformed into the yeast strain containing the AVO1 
bait plasmid to test the specificity of the positive plasmids. Two candidates were 
confirmed and sequenced. While the first clone contained only an intergenic region, the 
second clone contained sequence from AVO3 (1.6 kb starting from nucleotide 456). To 
confirm the interaction AVO3 (nt 456-2052) and AVO3 (nt 456-1266) was cloned in the 
prey vector of the yeast two-hybrid system. We observed an interaction between full-
length AVO1 and AVO3 (152-684) but not AVO3 (152-422) confirming the interaction of 
AVO1 with the N-terminal part of AVO3 by yeast two-hybrid (data not shown). The part 
of AVO1 responsible for the interaction with AVO3 is unknown as different AVO1 
versions (AVO1(1-420), AVO1(380-790), AVO1(690-1176)) failed to interact with AVO3 
by yeast two-hybrid assay suggesting that many binding regions are required for AVO1 
to associate with AVO3 (data not shown). Thus, AVO1 binds to a region in the N-
terminal part of AVO3 by yeast two-hybrid. 
 
 
AVO1 contains a conserved domain essential for its function 
AVO1 is a protein consisting of 1176 amino acids. Sequence analysis by SMART 
analysis (smart.embl-heidelberg.de) revealed that AVO1 does not contain any known 
domains or motifs. The weak RAS-interacting domain in the C-terminal part of AVO1 
identified in an earlier analysis could not be confirmed. Alignment with putative 
homologues indicated that the most conserved region lies in the C-terminal part of 
AVO1, in particular in a region between amino acid 735 and 764 (Fig. 3.4.D). Data 
base analyses revealed that this region is unique for AVO1 and its putative 
homologues as it is not found in other proteins. The N-terminal part of AVO1 does not 
share any similarities with its putative homologues. To identify regions that are required 
for the function of AVO1, deletion mutants of AVO1 were constructed and transformed 
into an avo1 strain containing AVO1 on an URA3-based plasmid. The growth 
phenotype of different AVO1 mutants was assayed after counterselection on  5-
fluorootic acid (5FOA) plates resulting in the loss of the URA3-based AVO1. Western 
blot analysis was performed to test whether all the mutant proteins are expressed (Fig. 
3.4.B). Deletion of the 420 amino acids at the N-terminus did not affect the functionality 
of AVO1, while deleting the 486 amino acids at the C-terminus resulted in a slight 
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growth phenotype (Fig. 3.4.A). However, cells expressing AVO1 (1-790) did not show a 
defect in the organization of the actin cytoskeleton (data not shown). Mutants that lack 
the most conserved region located between amino acid 735 and 764 were not able to 
restore viability of avo1 cells indicating that this region is important for the function of 
AVO1 (Fig. 3.4.C,D). Thus, C-terminal and N-terminal parts of AVO1 are not required 
for its function whereas a conserved domain between amino acid 735 and 764 is 
essential for the function of AVO1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. AVO1 contains a conserved domain essential for its function 
A) avo1 mutants expressing AVO1 from URA3-based plasmid (RL66-2d) were transformed with either 
empty plasmid, pAVO1(1-1176), pAVO1(421-1176), pAVO1(1-420), pAVO1(1-790), pAVO1 (∆647-793), 
pAVO1 (∆735-793), pAVO1 (∆776-793) and streaked onto selective plates lacking uracil and leucine (SD-
leu-ura) and onto plates containing 5-fluorootic acid (5FOA) to select against the URA3-based AVO1 
plasmid. 
B) Expression of the myc-, or HA-tagged constructs of AVO1 was checked by immunoblotting 
47
  
 
 
 
 
 
 
 
 
 
 
 
 
 
C) Summary of the AVO1-constructs used in this study 
D) Sequence alignment of a conserved region in AVO1 (from amino acid 735 to 764). Sequences of the 
putative AVO1 homologues in Ashbya gossybii, Schizosaccharomyces pombe (S. pombe), mus musculus 
(mouse) and homo sapiens (human) are aligned. 
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3. 3. Discussion 
 
TORC2 consisting of the proteins TOR2, AVO1, AVO2, AVO3 and LST8 is required for 
the spatial control of cell growth, which is the organization of the actin cytoskeleton. 
TORC2 controls the cell cycle dependent organization of the actin cytoskeleton by 
activating the RHO1 GTPase via the exchange factor ROM2. Activated RHO1 signals 
to the actin cytoskeleton by binding to PKC1 leading to the activation of the cell 
integrity MAP kinase cascade.  Here we analyzed the phenotypes of avo1 and lst8 
mutant cells and characterized the AVO1 protein. We showed that upregulation of the 
RHO1 GTPase switch or the PKC1-MAP kinase cell integrity pathway suppressed the 
growth defect and partially rescued the actin defect of cells depleted for AVO1 or LST8 
confirming a role of these two proteins in the signaling branch controlled by TORC2. 
Previously identified suppressors of tor2 suppress an lst8 mutant very poorly, likely 
because LST8 has multiple cellular functions, as it is not only a member of TORC2 but 
also part of the rapamycin-sensitive TORC1. The phenotype of LST8-defecient cells 
might therefore be a complex overlap of different functions. Surprisingly, multicopy 
YPK2 restores growth of lst8 cells very efficiently suggesting that overexpression of 
YPK2 suppresses all essential functions of LST8. There is evidence for a relationship 
between the TORC2 signaling pathway and the PKH-YPK pathway because both 
pathways appear to impinge on the same readouts. First, PKHs are stimulated by 
sphingoid bases and TOR2 as well as AVO3 were identified as mutations that 
suppress csg2, a gene involved in sphingolipid biosynthesis (Dunn et al., 1998; Friant 
et al., 2001). Additionally, overexpression of SUR1, whose gene product also functions 
in sphingolipid biosynthesis, suppresses a tor2 mutant (Helliwell et al., 1998a). Second, 
similar to mutants of TORC2, ypk mutant cells display an actin defect and reduced 
activation of the MAP kinase MPK1. The lethality of ypk cells is also suppressed by 
activation of the RHO1 GTPase switch as well as by the activation of the PKC1-MAP 
kinase signaling cascade (Schmelzle et al., 2002). Third, in S. pombe overexpression 
of GAD8, the orthologue of YPKs, suppresses the sterility of tor1 mutant (Matsuo et al., 
2003). The phosphorylation of GAD8 is dependent on TOR1 and KSG1, the orthologue 
of PKHs. TOR1 appears to be responsible for the phosphorylation of the turn motif and 
the hydrophobic motif while KSG1 directly phosphorylates the Thr in the activation 
loop. A similar situation is found in higher eukaryotes where p70S6K is phosphorylated 
by PDK1, the PKH orthologue, at the activation loop and by mTOR at the hydrophobic 
motif (Alessi et al., 1998; Burnett et al., 1998). Similarly, bacterial expressed YPKs 
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appear to be phosphorylated in a TORC2-dependent manner in vitro supporting a 
model in which YPKs receives signals from the sphingolipid-stimulated PKHs and the 
nutrient-controlled TOR kinase (R. Loewith, W. Oppliger unpublished). Thus, TORC2 
might impinge on YPKs to control organization of the actin cytoskeleton. YPKs also 
perform different functions as ypk1 mutant cells exhibit a defect in translation (Gelperin 
et al., 2002). Given the fact that YPKs are involved in both translation and actin 
cytoskeleton organization, processes controlled by TORC1 and TORC2, respectively, 
could explain the efficient suppression of lst8 by multicopy YPK2. 
 
Although the suppression of lst8 by overexpression of TOR2 is very weak, the result 
might indicate that LST8 is an upstream factor for the TOR signaling pathway. Since 
LST8 is present in both TOR complexes it may act as an upstream regulator of TOR by 
receiving signals from nutrients. Further experiments are needed to prove this 
hypothesis (see also Part 4 of this thesis). 
 
We did not identify novel interacting proteins of TORC2 performing biochemical 
purifications and a yeast two-hybrid screen. Because TORC2 seems to be associated 
with membranes interaction of TORC2 to its substrates might be mediated through 
membranes  (Kunz et al., 2000; Wedaman et al., 2003). Such interactions are lost in 
our biochemical purification procedures and likely cannot be detected by yeast two-
hybrid. However, AVO1 appears to interact with the N-terminal part of AVO3 by yeast 
two-hybrid, but whether AVO1 interacts directly with AVO3 or through another protein 
is unknown. AVO3 contains six conserved regions that are essential for its function (R. 
Shioda, unpublished). The first conserved region at the N-terminus (350-480) of AVO3 
overlaps with the AVO1 interaction domain suggesting a role of this conserved region 
in mediating interaction with AVO1. 
 
Additionally, we identified a conserved region in AVO1 that is important for the function 
of AVO1. This region possibly meditates binding of AVO1 to TOR2 or other proteins in 
TORC2 or is required for proper folding of AVO1. We cannot exclude that there are 
other regions in AVO1 that are important for the functionality of AVO1. Further 
experiments need to be performed to test whether the AVO1 deletion mutants are still 
part of TORC2. Identification of AVO1 mutants associating with the complex but 
exhibiting a growth phenotype could be interesting for identifying downstream effectors 
of TORC2.   
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3. 4. Material and methods 
 
Strains and media 
The S. cerevisiae strains and plasmids used are listed in Table 3.1. and 3.2., 
respectively. All strains are isogenic derivatives of JK9-3da or TB50a. Rich media, YPD 
or YPGal/Gly, and synthetic complete media, SD or SGal/Gly, were as described 
previously (Beck et al., 1999; Sherman, 1991). For TOR2-, and AVO1-depletion 
experiments, cells from logarithmically growing SGal/Gly or YPGal/Gly cultures were 
inoculated into SD or YPD medium, respectively. Glucose cultures were shaken for 15 
hr before cells were harvested for analysis. 
 
Genetic techniques 
Restriction enzyme digests and ligations were performed according to standard 
methods. All enzymes and buffers were obtained commercially (Roche Diagnostics). 
Escherichia coli strains MH1 and DH5α were used for propagation and isolation of 
plasmids. Yeast transformation was performed by the lithium acetate procedure (Ito et 
al., 1983). PCR cassettes were used to generate gene deletions and modifications, as 
described (Longtine et al., 1998; Puig et al., 2001) 
 
Actin staining 
Logarithmically growing cells were fixed in formaldehyde (3.7%) and potassium 
phosphate buffer (100 mM; pH 6.5) and stained with tetramethyl rhodamine 
isothiocyanate (TRITC)-phalloidin (Sigma) to visualize actin, as described previously 
(Benedetti et al., 1994). 
 
Two-hybrid assays 
Yeast two-hybrid assays were performed as described in (James et al., 1996). PJ69-4a 
cells were sequentially with a bait plasmid (pGBD-based) expressing a GAL4-BD (DNA 
binding domain) fusion protein and a prey plasmid or a library (pGAD-based) 
expressing a GAL4 AD (activation domain) fusion protein, and selected for the HIS3 
reporter on SD-ade-leu-trp plates.  
 
MAP kinase assay 
Yeast strains expressing HA-tagged MPK1 and AVO1 under the control of the GAL1 
promoter were grown in YPGal/Gly. Per time point, 50 ml of YPD was inoculated, 
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grown at 24°C for 16 hr (to an OD600 of 0.4) and subsequently shifted to 39°C for the 
indicated time. Samples were chilled with crushed ice, harvested by centrifugation, 
washed with ice-cold water and stored at -80°C. The cells were resuspended in 0.5 ml 
lysis buffer (50 mM Tris, pH 7.5, 10% glycerol, 1% Triton X-100, 0.1% SDS, 150 mM 
NaCl, 50mM NaF, 1 mM sodium orthovanadate, 50 mM β-glycerol phosphate, 5 mM 
sodium pyrophosphate, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride, and 1 x 
Roche complete protease inhibitor cocktail) and lysed by vortexing 5 x 30 s with glass 
beads using a FastPrep machine (Savant Instruments). A total of 30 µg protein (for 
anti-activated MAPK detection) or 15 µg protein (for anti-HA detection) was loaded per 
lane for electrophoresis (10% acrylamide). After SDS-PAGE the proteins were 
eletroblotted to nitrocellulose. To detect the proteins the membrane was first incubated 
in blocking buffer (1 x TBS, 0.1% Tween-20, 5% milk) and then over night at 4°C with 
mouse anti-HA antibody (1:10000 diluted in blocking buffer) or rabbit anti-MAP kinase 
activated (New England Biolabs) (1:2000 diluted in blocking buffer). Primary antibodies 
were detected using the corresponding horseradish peroxidase-conjugated secondary 
antibodies (1:5000 dilution) with ECL reagents (Amersham Pharmacia Biotech).  
 
TAP purification 
TAP purification was performed as described in (Puig et al., 2001). Extracts were 
prepared from a 4 l culture expressing TAP-tagged AVO1 grown in YPD at 30°C to an 
OD600 of 0.8. Cells were chilled on ice for 30 min, collected by centrifugation, washed 
once in ice-cold water and lysed with a Bead Beater (Biospec products) in ~40 ml lysis 
buffer (1 x TBS, 10% glycerol, 0.5% Tween-20 plus inhibitors: 10 mM NaF, 10 mM 
NaN3, 10 mM p-nitrophenylphosphate, 10 mM sodium pyrophosphate, 10 mM β-
glycerophophate, 1 mM phenylmethylsulfonyl fluoride, 1 x Roche complete inhibitor 
cocktail). Extracts were precleared by 500 µl Sepharose CL 4B (Sigma), and 
processed according to (Puig et al., 2001) except that 0.5% Tween-20 was used as 
detergent and the proteins were not eluted from the calmodulin-beads but directly 
resuspended and boiled in 2 x SDS-PAGE sample buffer. 
 
Immunoprecipitation 
Protein extracts were prepared as described above. To immunoprecipitate epitope 
tagged protein 1 µl of either concentrated 12CA5 (anti-HA) or 9E10 (anti-myc) tissue 
culture supernatant was added and the tubes were rotated for 1 hr at 4°C. Afterwards 
20 µl protein G-sepharose slurry (Sigma) was added and the tubes were rotated for 
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additional 2 hr at 4°C. Beads were collected by centrifugation, washed four times with 1 
ml lysis buffer, and resuspended in 2 x SDS-PAGE sample buffer. After SDS-PAGE the 
proteins were electroblotted onto nitrocellulose, blocked in 5% milk in 1 x PBS 0.1% 
Tween-20, and incubated with primary antibody (12CA5 or 9E10 1:10000 in blocking 
solution) over night at 4°C. The membranes were washed and incubated for 1 hr at 
room temperature with anti-mouse horseradish peroxidase-conjugated secondary 
antibody. The tagged proteins were detected using ECL reagents (Amersham 
Pharmacia Biotech).   
 
 
 
 
 
Table 3.1. Strains  
 
Strain  Genotype 
 
JK9-3da MATa leu2-3,112 ura3-52 trp1 his4 rme1 HMLa 
JK9-3dα MATα leu2-3,112 ura3-52 trp1 his4 rme1 HMLα 
TB50a  JK9-3da HIS4 his3 
TB50α  JK9-3dα HIS4 his3 
PJ69-4a MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆ LYS2::GAL1-
HIS3 GAL2-ADE2 met2::GAL7-lacZ 
RL23-1c TB50a [kanMX4]-GAL1p-AVO1 
RL57-2d TB50a [kanMX4]-GAL1p-LST8 
TS99-5c TB50a MPK1-3HA-kanMX4 
SW35-5c TB50a [kanMX4]-GAL1p-AVO1 MPK1-3HA-kanMX4  
SW45-1b TB50a AVO1-TAP-KlTRP1 
SW71-3a TB50a [kanMX4]-GAL1p-LST8 sac7::kanMX4 
SW48-1b TB50a [kanMX4]-GAL1p-AVO1 sac7::kanMX4 
RL66-2d TB50a avo1::kanMX4 / pRL8-2-1: YEplac195::myc-AVO1 
SW57-1d TB50a rom2::kanMX4 AVO1-TAP-KlTRP1 / pAS115: YCplac33::3HA-
ROM2 
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Table 3.2. Plasmids 
 
Plasmids   Description  
 
pROM2 pAS30; ROM2 in YEplac195 (2µm, URA3), 
 (Schmidt et al., 1997) 
pRHO2   pC-186; RHO2 (2µm, URA3) (Madaule et al., 1987) 
pPKC1 pSH24; PKC1 in pSEY18 (2µm, URA3),  
 (Helliwell et al., 1998b) 
pPKC1*   PKC1R398P in YCp50 (CEN, URA3), (Nonaka et al., 1995) 
pBCK1*   BCK1-20 in pRS316 (CEN, URA3), (Lee and Levin, 1992) 
pMKK1   MKK1 in YEp352 (2µm, URA3) 
pMKK1* MKK1S386P in YCplac33 (CEN, URA3),  
 (Watanabe et al., 1995) 
pMPK1   MPK1 in YEp352 (2µm, URA3), (Kamada et al., 1995) 
pTOR2   pJK3-3; TOR2 in pSEY18 (2µm, URA3),  
    (Kunz et al., 1993) 
pMSS4   pSH22; MSS4 in pSEY18 (2µm, URA3), 
    (Helliwell et al., 1998a) 
pYPK2    pTS96; YPK2 in YEplac195 (2µm, URA3) 
pAVO1 (1-1176) pSW59; expresses myc-tagged AVO1 (1-1176) from 
AVO1 promoter. Cloned as 3.9-kb SalI fragment into 
YEplac181::AVO1promoterATG-myc (2µm, LEU2) 
pAVO1 (421-1176) pSW50; expresses myc-tagged AVO1(421-1176) from 
AVO1 promoter. Cloned as 2.6-kb SalI fragment into 
YEplac181::AVO1promoterATG-myc (2µm, LEU2) 
pAVO1 (1-420) pSW11; expresses HA-tagged AVO1 (1-420) from AVO1 
promoter. Cloned as 1.5-kb XbaI-PstI fragment into 
pHAC181 (2µm, LEU2) 
pAVO1 (1-790) pSW12; expresses HA-tagged AVO1 (1-790) from AVO1 
promoter. Cloned as 2.7-kb XbaI-PstI fragment into 
pHAC181 (2µm, LEU2) 
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pAVO1 (∆647-793) pSW33; expresses HA-tagged AVO1 (∆647-793) from 
AVO1 promoter. Cloned as 2.2-kb XbaI-SalI and 1.5-kb 
SalI fragment into pHAC181 (2µm, LEU2) 
pAVO1 (∆735-793) pSW32; expresses HA-tagged AVO1 (∆735-793) from 
AVO1 promoter. Cloned as 2.4-kb XbaI-SalI and 1.5-kb 
SalI fragment into pHAC181 (2µm, LEU2) 
pAVO1 (∆776-793) pSW29; expresses HA-tagged AVO1 (∆776-793) from 
AVO1 promoter. Cloned as 2.5-kb XbaI-SalI and 1.5-kb 
SalI fragment into pHAC181 (2µm, LEU2) 
pGBD::AVO1 pSW7; AVO1 cloned as 3.5-kb SmaI-SalI fragment into 
pGBD-C1 (ADH1 promoter; 2µm, TRP1) 
pGBD::AVO1(1-420) pSW8; AVO1 (nt 1-1260) cloned as 1.3-kb SmaI-PstI 
fragment into pGBD-C1 (ADH1 promoter; 2µm, TRP1) 
pGBD::AVO1(380-790) pSW9; AVO1 (nt 1140-2370) cloned as 1.2-kb BamHI-
PstI fragment into pGBD-C1 (ADH1 promoter; 2µm, 
TRP1) 
pGBD::AVO1(690-1176) pSW10; AVO1 (nt 2070-3528) cloned as 1.5-kb SalI-SalI 
fragment into pGBD-C1 (ADH1 promoter; 2µm, TRP1) 
pGAD::RHO1 pSW19; RHO1C206S cloned as 0.6-kb BamHI-BglII 
fragment into pGAD-C1 (ADH1 promoter; 2µm, LEU2) 
from pETE25 (Schmidt et al., 1997) 
pGAD::RHO1(Q86H) pSW20; RHO1Q86H C206S cloned as 0.6-kb BamHI-BglII 
fragment into pGAD-C1 (ADH1 promoter; 2µm, LEU2) 
from pETE27 (Schmidt et al., 1997) 
pGAD::RHO1(G22A) pSW21; RHO1G22A C206S cloned as 0.6-kb BamHI-BglII 
fragment into pGAD-C1 (ADH1 promoter; 2µm, LEU2) 
from pAS92 (Schmelzle et al., 2002) 
pGAD::AVO3 (152-684) pSW30; AVO3 (nt 456-2052) cloned as 1.6-kb ClaI-PstlI 
fragment into pGAD-C1 (ADH1 promoter; 2µm, LEU2) 
pGAD::AVO3 (152-422)  pSW31; AVO3 (nt 456-1266) cloned as 0.8-kb ClaI-PstI 
fragment into pGAD-C1 (ADH1 promoter; 2µm, LEU2) 
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4. Functional analysis of TORC2 
 
4. 1. Introduction 
 
TOR signaling complexes 
Previously, we identified two TOR complexes (TORC1 and TORC2) in yeast, and at 
least one of these (TORC1) is conserved in man. While TORC1 mediates the 
rapamycin-sensitive signaling branch, TORC2 signaling is rapamycin-insensitive and 
responsible for the control of the actin cytoskeleton. TORC1 consists of four proteins, 
TOR1 or TOR2, KOG1, TCO89 and LST8, and with the exception of TCO89, all of 
these proteins are evolutionarily conserved. TORC2 comprises seven proteins, TOR2, 
AVO1, AVO2, AVO3, LST8 and the recently identified BIT61 and BIT2 (Loewith et al., 
2002; Reinke et al., 2004).  
 
Raptor is the highly conserved mammalian orthologue of KOG1. It has a molecular 
mass of 150 kDa and was identified independently by three different groups (Hara et 
al., 2002; Kim et al., 2002; Loewith et al., 2002). At its N-terminus raptor and its 
orthologues contain a domain named RNC (raptor N-terminal conserved) consisting of 
three blocks with at least 67-79% sequence similarity. The RNC domain appears to be 
unique to raptor and its orthologues, as it is not found in other protein sequences in 
public databases. The RNC domain is followed by three HEAT repeats and the C-
terminal third of raptor contains seven WD40 repeats.  
 
mLST8 is a protein of 36 kDa and consists almost entirely of seven WD40 repeats (Kim 
et al., 2003; Loewith et al., 2002). The WD40 repeat is characterized by a set of 
conserved residues within a repeat length of around 40 amino acids. mLST8 shows 
sequence similarity to the β subunits of heterotrimeric G proteins. In analogy to the G 
protein β1 subunit that contains six WD40 repeats folding into a cylindrical β-propeller 
structure, mLST8 is thought to have a β-propeller structure. 
 
Raptor interacts with the N-terminal, HEAT repeats containing part of mTOR 
underscoring the function of HEAT repeats as mediators of protein-protein interactions 
(Kim et al., 2002). The association between raptor and mTOR involves multiple sites in 
raptor suggesting that mTOR and raptor make extensive contacts with each other. 
However, the mTOR-raptor interaction is very sensitive to detergents. A stable 
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association of both proteins can only be detected in buffer containing no detergents or 
0.3% CHAPS; lysis buffers with Triton X-100 or NP-40 as detergent eliminates the 
interaction (Hara et al., 2002; Kim et al., 2002).  
 
Raptor, like its orthologue in yeast KOG1, appears to be a positive regulator of TOR 
since raptor is required for the optimal phosphorylation of 4E-BP1 and p70S6K in 
nutrient-stimulated cells. The mechanism by which raptor modulates these downstream 
effectors is controversial. The first model, presented by the group of Sabatini, proposes 
a mechanism by which raptor and mTOR form a nutrient-sensitive complex and raptor 
both positively and negatively regulates mTOR function (Kim et al., 2002). Nutrients 
seem to affect the stability of mTOR-raptor complex. Deprivation of leucine or other 
nutrients such as glucose but not removal of growth factors leads to a stabilization of 
mTOR-raptor interaction and to a decrease in p70S6K phosphorylation, while 
readdition of nutrients reverses the effect. This inverse correlation between the stability 
of mTOR-raptor association and the phosphorylation of p70S6K lead to the suggestion 
that a strong interaction between raptor and mTOR results in an inhibition of the mTOR 
kinase activity. Apart from this negative regulation, raptor positively modulates mTOR 
as raptor downregulation by siRNA reduces p70S6K phosphorylation leading to a 
model in which raptor interacts with mTOR under all nutrient conditions but with 
different affinities. Under good nutrients conditions raptor forms a rather unstable 
complex with mTOR that is required for mTOR function. On the other hand, under 
nutrient-poor conditions mTOR-raptor complex is stabilized resulting in the inhibition of 
mTOR kinase activity. 
 
In contrast to this model the group of Yonezawa fails to detect a nutrient-sensitive 
interaction between raptor and mTOR (Hara et al., 2002). In addition, experiments in 
yeast indicated that TOR1 or TOR2 forms a stable complex with KOG1 independently 
of the nutritional state of the cell (Loewith et al., 2002). Raptor might rather function as 
a scaffold protein bringing mTOR kinase in proximity to its substrates. Consistent with 
this model raptor is able to bind to 4E-BP1 and p70S6K1. The binding of raptor to 4E-
BP1 increases if the rapamycin-sensitive phosphorylation sites in 4E-BP1 are changed 
to alanine and decreases if the same amino acids are mutated to glutamic acid 
indicating a preferential binding of raptor to the nonphosphorylated form of 4E-BP1.  
Reducing the amount of raptor by RNA interference results in a decrease in 4E-BP1 
phosphorylation underscoring the requirement of raptor for the phosphorylation of 4E-
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BP1 (Hara et al., 2002). The RAIP motif (in the N-terminus) and the TOS motif (in the 
C-terminus) are both required for the efficient phosphorylation of 4E-BP1 (Beugnet et 
al., 2003; Schalm and Blenis, 2002). Mutation of the TOS motif in 4E-BP1 abolishes 
the binding of 4E-BP1 to raptor indicating the requirement of a functional TOS motif in 
the assembly of mTOR-raptor-4E-BP1 complex (Schalm et al., 2003). Thus, the TOS 
motif seems to mediate the association between 4E-BP1 to raptor supporting the 
model in which raptor acts as a scaffold protein that presents the mTOR kinase to its 
downstream substrates.   
 
A second interactor of mTOR, mLST8 exerts a positive role on mTOR function (Kim et 
al., 2003). Unlike raptor, mLST8 binds to the mTOR kinase domain in a constitutive, 
detergent-, and nutrient-insensitive manner. Depletion of mLST8 using siRNA blocks 
the activation of p70S6K in response to growth factors and nutrients. On the other 
hand, overexpression of mLST8 stimulates mTOR activity towards p70S6K and 
enhances the association of raptor to mTOR, which is inconsistent with the model that 
strong binding of raptor would inhibit mTOR activity. While raptor does not affect the 
binding of mLST8 to mTOR, depletion of mLST8 destabilizes the interaction between 
raptor and mTOR implying a role of mLST8 in the formation of the mTOR complex. The 
function of raptor and mLST8 in the mTOR complex, especially in respect to the 
formation of a nutrient-sensitive complex remains controversial. 
 
 
 
TORC2 in yeast 
During my thesis I was interested in the function of the components that form TORC2. 
While the phenotypical analysis of TORC2 partners indicated that they perform a 
positive role in the rapamycin-insensitive TOR2-unique signaling branch, the molecular 
function and mechanism by which these proteins control the TOR2-unique branch 
remained to be elucidated.  
 
TORC2 contains at least five proteins, TOR2, AVO1, AVO2, AVO3 and LST8, and 
forms a stable complex. So far we were not able to identify other components of 
TORC2 or more transient interactors of the complex, which could serve as signaling 
molecules. Nevertheless, the group of Ted Powers identified an additional component 
of TORC2, named BIT61(Reinke et al., 2004). BIT61 is a nonessential protein and 
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bit61 mutant cells do not show any obvious growth defect under different growth 
conditions. Database analysis revealed that BIT61 has a homologue in the yeast 
genome, YBR270C (named BIT2), which could be redundant to BIT61. Although BIT2 
interacts with TOR2, a double mutant of bit61bit2 behaves like a wild- type when grown 
under various growth conditions (Ryo Shioda, unpublished). The role of these two 
proteins in TORC2 is unknown. 
 
Recently, novel components of TORC2 signaling pathway have been identified. In a 
global yeast two-hybrid screen two uncharacterized proteins, YIL105C and YNL047C 
were identified as interactors of AVO2 (Uetz et al., 2000). Additionally, YIL105C was 
pulled out as a genetic interactor of MSS4 in a synthetic lethal screen (Audhya et al., 
2004). Sequence analysis revealed that YNL047C is 53% identical to YIL105C. 
Whereas the single deletion mutants are viable the double yil105c ynl047c mutant is 
lethal indicating a redundancy of the two proteins (Audhya et al., 2004). YIL105C and 
YNL047C were named SLM1 and SLM2, respectively. The SLM proteins contain a lipid 
binding PH domain and preferentially bind to PI4,5P2. They localize to the cell 
periphery and the localization is at least partly dependent on the lipid kinase MSS4 as 
the SLMs show an enhanced cytoplasmic localization in mss4 mutant cells. Thus, 
MSS4-generated PI4,5P2 is important for the recruitment of SLMs to the plasma 
membrane. Similar to mss4 mutant cells a temperature sensitive slm1ts slm2 exhibits a 
defect in the organization of the actin cytoskeleton at restrictive temperature. This actin 
defect is suppressed by overexpression of multicopy PKC1 but not by BCK1 or MKK1. 
Additionally, deletion of SAC7, which encodes a GAP for RHO1, could rescue the 
lethality of a slm1 slm2 double mutant. PKC1 could only restore viability of the 
temperature-sensitive slm1 strain when grown at 26°C but not under heat shock 
conditions implying that other RHO1 effectors may also be required. SLM1 and SLM2 
are able to interact with each other and are phosphoproteins. As predicted by the yeast 
two-hybrid analysis SLM1 coimmunoprecipitates with AVO2, although the interaction is 
very unstable leading to the suggestion that the SLM proteins might be substrates for 
TORC2 rather than stable components of TORC2. Indeed, TORC2 phosphorylates 
recombinant SLM1 and SLM2 in vitro (Audhya et al., 2004). This suggests that the 
SLMs are substrates of TORC2 through which TORC2 signals to the actin 
cytoskeleton. Thus, the SLM proteins seem to require two different signals to perform 
their function. One signal is generated by the lipid kinase MSS4 and leads to the proper 
localization of the two proteins. The second signal comes from TORC2 that 
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phosphorylates both proteins. Further work has to be performed to clarify the 
significance of the TORC2-mediated phosphorylation of the SLMs as well as their 
function in the organization of the actin cytoskeleton.    
 
TORC2 consisting of the proteins TOR2, AVO1, AVO2, AVO3 and LST8 is a stable 
complex (Loewith et al., 2002). The interaction of the different proteins is constitutive 
and is not sensitive to nutrient conditions. Phenotypic analyses revealed that TORC2 is 
important for the organization of the actin cytoskeleton. The function of the different 
proteins in the complex as well as the architecture of the TORC2 is unknown. Here we 
analyze the architecture of TORC2 as well as the function of components of TORC2 in 
yeast. We provide evidence that AVO1 and possibly AVO3 act as scaffold proteins 
important for the integrity of TORC2 and are required for efficient phosphorylation of 
downstream target proteins. LST8 appears to be involved in modulating the kinase 
activity of TOR2. 
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4. 2. Results 
 
TORC2 exists in an oligomeric form 
Gel filtration experiments indicated that TOR2 forms a stable complex of 2 M Da 
(Loewith et al., 2002). Summing the molecular weights of TOR2 and its partners results 
in a mass of 0.78 M Da (including BIT61 and BIT2) suggesting that TORC2 might exist 
in a multimeric state. To check whether the components of TORC2 can interact with 
themselves coimmunoprecipitation experiments were performed. As shown in Fig. 
4.1.A) every component of TORC2 tested is able to oligomerize suggesting that 
TORC2 exists in an oligomeric state. Most likely TORC2 dimerizes which would be 
consistent with the molecular weight observed by gel filtration.  
 
Under nitrogen starvation conditions TOR signaling is inhibited. The mechanism by 
which TOR is inhibited is unknown. Since nitrogen starvation does not affect the 
association of TOR2 with its partners, the activity of TORC2 could be regulated through 
its dimerization. To test this possibility TOR2 dimerization was analyzed in cells that 
were starved of nitrogen for 60 min. The interaction of TOR2 with itself was unaffected 
upon nitrogen starvation (Fig. 4.1.B). Thus, TORC2 exists in a dimeric or higher order 
state which is unaffected by nitrogen starvation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61
  
 
 
 
 
 
 
 
 
Figure 4.1. TORC2 exists in an oligomeric form 
A) Lysates from cells expressing HA-TOR2 and myc-TOR2 (SW70 transformed with pAN54), AVO1-HA 
and AVO1-TAP (SW110), AVO3-HA and AVO3-myc (SW112) or AVO2-HA and AVO2-myc (SW111) were 
subjected to immunoprecipitation with anti-myc or pulldown with IgG-sepharose and probed with anti-myc 
or anti-ProteinA to check expression of myc- or TAP-tagged proteins (lane 4, expression 2) and with anti-
HA (lane 3, coIP) to test for coimmunoprecipitation. Expression of HA-tagged proteins was detected by 
immunoprecipitation with anti-HA and probed with anti-HA (lane 2, expression 1). As negative control 
lysates from cells expressing HA-TOR2 (SW70), AVO1-HA (RL69-1c), AVO3-HA (RL42-1c) or AVO2-HA 
(RL39-1a) were subjected to immunoprecipitation with anti-myc and probed with anti-HA (lane 1).   
 
B) Lysates from cells expressing HA-TOR2 and mycTOR2 (SW70 transformed with pAN54) grown in 
medium containing ammonium as nitrogen source (lane 2) or nitrogen starved for 1 hr (lane 3) were 
subjected to immunoprecipitation with anti-myc. Immunoprecipitates were probed with anti-HA to detect 
coimmunoprecipitated TOR2 (bottom panel, coIP). As negative control lysate from cells expressing HA-
TOR2 (SW70) transformed with empty plasmid were subjected to immunoprecipitation with anti-myc and 
probed with anti-HA (lane 1, bottom panel, coIP). The expression of HA or myc-tagged TOR2 detected by 
immunoprecipitation is shown in the top panel and middle panel, respectively. 
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AVO1 and AVO3 are important for the structural integrity of TORC2 
To study the contribution of TORC2 components to TORC2 architecture we shut off 
expression of TORC2 components and assayed complex integrity by looking at 
coimmunoprecipitation of the remaining components. Since all the proteins of TORC2 
except AVO2 are essential we depleted cells of an essential partner by replacing its 
own promoter with the GAL1 promoter and turning off its expression in glucose-
containing media. Interaction of TORC2 components was examined by comparing cells 
grown in galactose-media to cells depleted of a TORC2 component grown in glucose-
media. Cells depleted for a protein will also be referred as mutant cells. 
 
To investigate the role of AVO1 in the architecture of TORC2 possible interactions 
between the different TORC2 proteins were analyzed in avo1 mutants by 
coimmunoprecipitations. The expression levels of the analyzed proteins did not vary by 
changing the media from galactose to glucose. As shown in Fig. 4.2. depletion of AVO1 
affected the integrity of TORC2. AVO2 as well as AVO3 no longer interact with TOR2 
(Fig. 4.2.A,B) and were also not able to associate with each other (Fig. 4.2.C) when 
AVO1 was depleted. On the other hand, the association of TOR2 and LST8 was not 
dependent on the presence of AVO1 (Fig. 4.2.D). Because TOR2 and LST8 are both 
components of TORC1 coimmunoprecipitation of this two proteins could be misleading. 
To ensure that the interaction between TOR2 and LST8 in avo1 was not due to 
TORC1, cell extracts were depleted for TORC1 by precipitating KOG1, a component of 
TORC1. TAP-tagged KOG1 was precipitated by incubating the cell extract with IgG-
sepharose prior to the coimmunoprecipitation experiment. TOR2 still associated with 
LST8 in absence of AVO1 and TORC1 indicating that the major part of TOR2 is in 
TORC2 (data not shown). Thus, AVO1 appears to be important for the association of 
AVO2 and AVO3 to TORC2 and does not affect the interaction between TOR2 and 
LST8. Consistent with this result AVO2 and AVO3 interactions with LST8 were lost in 
avo1 mutant cells (Fig. 4.2.E,F). 
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Figure 4.2. AVO1 is required for AVO2 and AVO3, but not for LST8 to associate 
with TORC2 
Lysates from cells expressing GAL1 promoter-AVO1 and HA- or myc-tagged versions of two TORC2 
components were subjected to immunoprecipitations with anti-HA or anti-myc. Cells expressing AVO1 
grown in galactose medium (lane 1) were compared to AVO1-depleted cells grown for 15 h in glucose 
medium (lane 2). Immunoprecipitates were probed with anti-myc or anti-H, respectively to detect the 
coimmunoprecipitated partner protein (bottom panel). The expression level of the HA or myc-tagged 
TORC2 component is shown in the top panel and middle panel, respectively. 
 A) GAL1pAVO1 HA-TOR2 AVO2-myc (SW76-5b), B) GAL1pAVO1 HA-TOR2 AVO3-myc (SW68-3b), C) 
GAL1pAVO1 AVO3-HA AVO2-myc (SW73-4b), D) GAL1pAVO1 HA-TOR2 LST8-myc (SW75-10c), E) 
GAL1pAVO1 LST8-HA AVO2-myc (SW69-4d), F) GAL1pAVO1 LST8-HA AVO3-myc (SW74-11b) 
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In avo3 mutant cells the association of TOR2 and AVO2 was impaired (Fig. 4.3.A), 
while the interaction of TOR2 with LST8 was unaffected (Fig. 4.3.B). Likewise AVO3 
was required for AVO1 and AVO2 to interact (Fig. 4.3.C) and the interaction between 
AVO1 or AVO2 and LST8 was abolished in avo3 mutant cells (Fig. 4.3.D,E). Therefore 
the binding of AVO1 and AVO2 to TORC2 is dependent on the presence of AVO3 
suggesting that AVO2 binds through both AVO1 and AVO3 to TORC2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. AVO3 is required for AVO1 and AVO2, but not LST8 to associate to 
TORC2 
Lysates from cells expressing GAL1 promoter-AVO3 and HA- or myc-tagged versions of two TORC2 
components were subjected to immunoprecipitations with anti-HA or anti-myc. Cells expressing AVO3 
grown in galactose medium (lane 1) were compared to AVO3-depleted cells grown for 15 hr in glucose 
medium (lane 2). Immunoprecipitates were probed with anti-myc or anti-HA, respectively to detect the 
coimmunoprecipitated partner protein (bottom panel). The expression level of the HA or myc-tagged 
TORC2 component is shown in the top panel and middle panel, respectively. A) GAL1pAVO3 HA-TOR2 
AVO2-myc (SW72-5a), B) GAL1pAVO3 HA-TOR2 LST8-myc (SW77-5d), C) GAL1pAVO3 AVO1-HA 
AVO2-myc (SW65-11c), D) GAL1pAVO3 AVO1-HA LST8-myc (SW67-3b), E) GAL1pAVO3 LST8-HA 
AVO2-myc (SW78-3a) 
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Consistent with this model AVO3 interacted with TOR2 in an avo2 mutant (Fig. 4.4.A) 
and deletion of AVO2 did not disturb the association between TOR2 and LST8 (Fig 
4.4.B). On the other hand, we observed that removal of LST8 destabilized but did not 
completely abolish the TOR2-AVO3 or the TOR2-AVO2 interaction (Fig. 4.4.C,D). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Effect of avo2, lst8 and tor2 on the integrity of TORC2 
A, B) AVO2 is not required for AVO1 and LST8 to interact with TOR2 
Lysates from wild-type (lane1) or avo2 mutant cells (lane 2) expressing HA- or myc-tagged versions of two 
TORC2 components were subjected to immunoprecipitations with anti-HA or anti-myc. Immunoprecipitates 
were probed with anti-HA to detect the coimmunoprecipitated partner protein (bottom panel). The 
expression level of the HA or myc-tagged TORC2 component is shown in the top panel and middle panel, 
respectively. 
A) HA-TOR2 AVO3-myc (SW62-7a),  avo2 HA-TOR2 AVO3-myc (SW102-8b), B) HA-TOR2 LST8-myc 
(SW63-1d), avo2 HA-TOR2 LST8-myc (SW103-2d) 
 
 
 
 
To examine whether AVO1 and AVO3 can interact independently of TOR2 forming a 
subcomplex, the association between AVO1, AVO2 and AVO3 was studied in TOR2-
depleted cells. As shown in Fig. 4.4.E,F the interaction between AVO1 and AVO3 was 
destabilized and AVO1 no longer bound to AVO2 in absence of TOR2 leading to the 
conclusion that TOR2 is required for the interaction of AVO1 to AVO2 and AVO3. 
Thus, AVO1, AVO3 and TOR2 appear to function as important structural elements of 
TORC2 and are required for AVO2 to bind to the complex. LST8 binds directly to TOR2 
(see below) independently of AVO1, AVO2 and AVO3 function. 
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C, D) Depletion of LST8 destabilizes the interaction between AVO3 and AVO2 
with TOR2  
Lysates from cells expressing GAL1 promoter-LST8 and HA- or myc-tagged versions of two TORC2 
components were subjected to immunoprecipitations with anti-HA or anti-myc. Cells expressing LST8 
grown in galactose medium (lane 1) were compared to LST8-depleted cells grown for 15 hr in glucose 
medium (lane 2). Immunoprecipitates were probed with anti-myc to detect the coimmunoprecipitated 
partner protein (bottom panel). The expression level of the HA or myc-tagged TORC2 component is shown 
in the top panel and middle panel, respectively. 
 C) GAL1pLST8 HA-TOR2 AVO3-myc (SW104-3c), D) GAL1pLST8 HA-TOR2 AVO2-myc (SW104-3c) 
 
E, F) AVO1 does not interact with AVO3 or AVO2 in cells depleted for TOR2 
Lysates from cells expressing GAL1 promoter-TOR2 and HA- or myc-tagged versions of two TORC2 
components were subjected to immunoprecipitations with anti-HA or anti-myc. Cells expressing TOR2 
grown in galactose medium (lane 1) were compared to TOR2-depleted cells grown for 15 hr in glucose 
medium (lane 2). Immunoprecipitates were probed with anti-myc to detect the coimmunoprecipitated 
partner protein (bottom panel). The expression level of the HA or myc-tagged TORC2 component is shown 
in the top panel and middle panel, respectively.  
E) GAL1pTOR2 AVO1-HA AVO3-myc (SW105-3d), F) GAL1pTOR2 AVO1-HA AVO2-myc (SW106-5a) 
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LST8 binds to the C-terminal part of TOR2 while AVO3 associates with the N-
terminal part of TOR2 
To determine which domains in TOR2 mediate the interaction between the different 
partner proteins coimmunoprecipitation experiments were performed. N-terminally 
tagged versions of TOR2 were expressed from high copy plasmids in strains containing 
epitope tagged TOR2 partner proteins. LST8 was able to interact with the C-terminal 
half of TOR2 containing the FAT, FRB and the kinase domain, but not with the N-
terminal half of TOR2 (Fig. 4.5.A). The binding of AVO1 and AVO3 to TOR2 appeared 
to be more complex because in cells expressing endogenous TOR2 we failed to detect 
an interaction of these two proteins with either the N-terminal or the C-terminal half of 
TOR2. Therefore, endogenous TOR2 was depleted using a strain that contains 
endogenous TOR2 under the control of the GAL1 promoter. In cells grown in glucose-
media we observed a weak interaction between AVO3 and the N-terminal half of TOR2 
consisting of the HEAT repeats but not with the C-terminal half of TOR2 (Fig. 4.5.B). 
However, using this approach we did not detect an interaction between AVO1 and the 
two TOR2 constructs suggesting that AVO1 might bind to TOR2 via multiple contacts 
with various domains of TOR2. Thus, AVO3 seems to associate with the HEAT repeats 
of TOR2, while LST8 avidly binds to the C-terminal half of TOR2. 
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Figure 4.5. Interaction domains of TOR2 with LST8 and AVO3 
A) LST8 binds to the C-terminal part of TOR2. 
Cells containing myc-tagged LST8 (RL59-2d) were transformed with pSW61 expressing the N-terminal half 
of HA-tagged TOR2 (amino acids 1-1390) and pSW62 expressing the C-terminal half of HA-tagged TOR2 
(amino acids 1290-2474). Lysates were incubated with anti-HA and subsequently probed with anti-myc to 
detect coimmunoprecipitated LST8 (bottom panel). 
B) AVO3 associates with the N-terminal part of TOR2 
Cells containing GAL1 promoter-TOR2 and myc-tagged AVO3 (SW94-1a) were transformed with pSW61 
expressing the N-terminal half of HA-tagged TOR2 (amino acids 1-1390) and pSW62 expressing the C-
terminal half of HA-tagged TOR2 (amino acids 1290-2474). Lysates were incubated with anti-myc and 
subsequently probed with anti-HA to detect coimmunoprecipitated TOR2 (bottom panel). 
 
 
 
 
 
LST8 controls TOR2 kinase activity and AVO1 functions as scaffold protein 
The coimmunoprecipitation experiments indicated that AVO1 as well as AVO3 are 
important structural proteins to maintain the integrity of the TORC2 without affecting the 
binding of LST8 to TOR2. To study the contribution of TORC2 components to kinase 
activity the activity of immunopurified TORC2 depleted of various partner proteins was 
determined in an in vitro kinase assay using as a substrate 4E-BP1 (a substrate of 
mammalian TOR). To control for specificity, activity from a mock purification was 
compared to the activity of immunopurified TOR2. We did not detect phosphorylation of 
4E-BP1 in the mock assay and obtained proteins of TORC2 but not TORC1 using 
immunopurified TORC2 demonstrating the feasibility of the assay (see also Fig. 5.2. in 
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Part 5 and data not shown). As a further control the phosphorylation status of 4E-BP1 
phosphorylation was analyzed using a kinase dead version of TOR2. Compared to 
wild-type TOR2, kinase dead TOR2 drastically reduced phosphorylation of 4E-BP1 
indicating that 4E-BP1 is phosphorylated in a TOR2-dependent manner (Audhya et al., 
2004).  
 
In vitro 4E-BP1 is unstructured and phosphorylated by a number of unrelated kinases. 
Therefore we consider 4E-BP1 to be a nonphysiological substrate for TOR2 in yeast, 
which allows studying the catalytic activity of TOR2 independently of the integrity of 
TORC2. To test linearity of the in vitro kinase assay time course experiments were 
performed. In wild-type as well as in cells depleted for AVO1 or LST8 the rate of 4E-
BP1 phosphorylation was linear up to 30 min incubation time (data not shown). The 
activity of TOR2 towards 4E-BP1 was determined by performing kinase reactions in the 
presence of different concentrations of 4E-BP1 and subsequent quantification of 4E-
BP1 phosphorylation. The phosphorylation was normalized to the amount of TOR2 
present in the kinase reaction determined by immunoblotting. The kinetic analysis is 
shown as a Lineweaver-Burk double reciprocal plot that allows the determination of the 
KM (Michealis-Menten constant; -1/X intercept) and the relative Vmax (maximal velocity; 
1/Y intercept ). The KM and relative Vmax of 4E-BP1 in avo1 mutants was not 
significantly changed compared to wild-type cells (Fig. 4.6.C). In lst8 mutant cells we 
observed a slight increase in the KM and a 2-fold decrease in relative Vmax compared to 
wild-type cells indicating that in the absence of LST8 the catalytic kinase activity of 
TOR2 is perturbed (Fig. 4.6.C). Because AVO1 depletion, which results in the 
disruption of TORC2 integrity, did not change the TOR2-mediated phosphorylation of 
4E-BP1 we conclude that AVO1 is not required for the regulation of TORC2 catalytic 
activity. Depletion of LST8 in contrast, suggests that LST8 modulates the kinase 
activity of TOR2. 
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Figure 4.6. LST8 controls TOR2 kinase activity  
In vitro kinase assays were performed using HA-TOR2 immunopurified from wild-type (SW70), GAL1 
promoter-AVO1 (SW84-1d) or -LST8 (SW100-1a) cells grown in glucose medium for 15 hr to deplete 
AVO1 or LST8. Purified HA-TOR2 was incubated with different concentrations of 4E-BP1 (from 0.15 - 0.45 
µM) in the presence of 32P-ATP. 
A) Phosphorylation (top panel) and amount of 4E-BP1 (bottom panel) 
B) Expression of HA-TOR2 purified from wt, avo1 and lst8 cells detected by immunoblotting  
C) Analysis of the normalized data shown as Lineweaver-Burk plot. X-axis represents the reciprocal value 
of 4E-BP1 concentrations in µM and Y-axis shows the reciprocal value of 4E-BP1 phosphorylation in 
arbitrary units.  X intercept defines -1/KM, and Y intercept 1/Vmax. 
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To investigate if the integrity of TORC2 affects the accessibility of in vivo substrates, 
kinase assays using recombinant SLM1 were performed. SLM1 was recently found to 
be a substrate of TORC2 (Audhya et al., 2004). To estimate the KM of the kinase 
reaction, various concentrations of bacterial expressed SLM1 were incubated with 
TORC2 purified from wild-type, avo2 or avo1 cells in the presence of 32P-ATP. 
Quantification of the phosphorylation and data analysis in the Lineweaver-Burk plot 
exhibited a 4-fold increase of the KM in avo1 but only a slight increase in avo2 cells 
when compared to the KM in wild-type cells (Fig. 4.7.C). The increased KM for SLM1 
without changing relative Vmax of the reaction indicates that the depletion of AVO1 
inhibits binding of SLM1 to the TOR2 kinase. Thus, AVO1 appears to act as scaffold 
and adaptor protein facilitating an efficient binding of substrates to TORC2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. AVO1 functions as scaffold and adaptor protein 
In vitro kinase assays were performed using immunopurified TOR2 from wild type (SW70), avo2 (SW92-
5a) or GAL1 promoter-AVO1 (SW84-1d) containing cells grown in glucose medium for 15 hr to deplete 
AVO1. Immunopurified TORC2 was incubated with different concentrations of recombinant GST-SLM1 
(from 0.1 -  2.7 µM) in the presence of 32P-ATP. 
A) Phosphorylation (top panel) and amount of SLM1 (bottom panel) 
B) Expression of HA-TOR2 purified from wt, avo1 and avo2 cells detected by immunoblotting  
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C) Analysis of the normalized data shown as Lineweaver-Burk plot. X-axis represents the reciprocal value 
of GST-SLM1 concentrations in µM and Y-axis shows the reciprocal value of SLM1 phosphorylation in 
arbitrary units.  X intercept defines -1/KM, and Y intercept 1/Vmax. 
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4. 3. Discussion 
 
Here we analyzed the architecture and the function of different components of TORC2. 
We showed that TORC2 exists in an oligomeric form and that AVO1 and AVO3 are 
scaffold and likely also adaptor proteins, whereas LST8 controls the catalytic activity of 
TOR2 protein kinase. 
 
The dimerization of TORC2 could be important for regulation of its activity. It has been 
recently reported that the activity of ATM, a kinase, that belongs like TOR to the 
phosphatidylinositide 3-kinase (PI3K)-related superfamily, is regulated by its 
dimerization (Bakkenist and Kastan, 2003). In its inactive state ATM exists as a dimer. 
Upon irradiation leading to autophosphorylation and activation of ATM, the ATM dimer 
is dissociated and active ATM monomers are able to phosphorylate their substrates. 
Although the regulation of TORC2 is different in the sense that TORC2 is dimerized in 
its active form dimerization could be an important regulatory mechanism. However, we 
did not see a change in the dimerization state of TOR2 under conditions where TOR 
signaling is inhibited. It remains to be elucidated which role the different partner 
proteins play in the dimerization of TORC2. 
 
Based on coimmunoprecipitation of TORC2 partner proteins in the absence of an 
individual partner we propose a model in which AVO1 and AVO3 bind at least partly to 
the HEAT repeats of TOR2 cooperatively mediating the binding of AVO2 and possibly 
BIT61, BIT2 (preliminary data) to the complex, whereas LST8 binds to the C-terminal 
half of TOR2 independently of AVO1, AVO2 or AVO3 (model Fig. 4.8.). AVO2 might 
serve as an adaptor protein for substrates, such as SLM1, as SLM1 copurifies with 
AVO2. Given the fact that AVO2 is a nonessential gene and does not exhibit any 
growth phenotypes under various conditions efficient phosphorylation of substrates 
must also occur in avo2 mutants. Likewise we did not observe a drastic change in the 
KM for SLM1 to TOR2 in an avo2 mutant. The protein-protein interactions occurring in 
TORC2 appear to be rather complex and the association of a given protein to TORC2 
may involve binding to different partner proteins through various domains, as the 
interaction between AVO1, AVO2 and AVO3 is impaired in the absence of TOR2. 
 
In in vitro kinase assays using 4E-BP1 and SLM1 as substrates for the TOR2 protein 
kinase we could discriminate different functions for AVO1 and LST8. We showed that 
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the TORC2-mediated phosphorylation of 4E-BP1, a nonphysiological substrate for 
TORC2, is independent of AVO1, but requires the presence of LST8 as indicated by 
the decrease in the relative Vmax for in the absence of LST8. Thus, LST8 seems to 
regulate the catalytic activity of TOR2, likely by direct binding to the TOR2 kinase 
domain. Importantly, the disruption of TORC2 observed upon AVO1 or AVO3 depletion 
did not disturb the interaction between TOR2 and LST8 suggesting that the integrity of 
TORC2 is not needed for TOR2 to be active. In this respect the destabilization of 
TORC2 in LST8-depleted cells did not account for the inhibition of the TOR2 kinase 
activity towards 4E-BP1 and might rather be a consequence of the inhibitory effect 
upon LST8 depletion. The finding that depletion of AVO1 resulted in a decreased 
affinity of TOR2 for SLM1 leads to the conclusion that AVO1 might act as an adaptor 
protein. Consistent with the coimmunoprecipitation experiments AVO1 and possibly 
AVO3 are important structural elements forming a stable complex with TOR2 and 
thereby provide the structural basis for binding and efficient phosphorylation of 
downstream factors.  
 
What is the function of LST8? LST8 was first identified in a synthetic lethal screen with 
sec13 and was shown to be required for transport of amino acid permeases, such as 
the general amino acid GAP1 from Golgi to plasma membrane (Roberg et al., 1997). 
However, the effect of LST8 on GAP1 sorting appeared to be indirect and a 
consequence of LST8 acting in the TOR signaling pathway (Chen and Kaiser, 2003). 
LST8 is a constituent of both TORC1 and TORC2 acting positively with TOR in either 
complex (Chen and Kaiser, 2003; Loewith et al., 2002). Therefore, LST8 might perform 
similar functions in TORC1 and TORC2. It has been reported that LST8 and TOR1 are 
localized at endosomal and Golgi membranes and LST8 could be important for the 
proper localization of TORCs. However, in lst8 mutants TOR1 still associated with 
internal membranes indicating that LST8 does not mediate localization of TOR1 to 
membranes (Chen and Kaiser, 2003). Our data suggest that LST8 bound to the TOR2 
kinase domain is required for TOR2 kinase activity which is consistent with the function 
of mLST8 in mammals (Kim et al., 2003). The mechanism by which LST8 regulates 
TOR2 kinase activity is not known but LST8 could be important for proper folding of the 
kinase domain or could compete with inhibitory factors for binding to the TOR2 kinase 
domain. 
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What is upstream of TORC2? In yeast TOR responds to nutrients, in particular to the 
quantity and quality of the nitrogen source. Through which mechanism the nutrient 
availability is sensed by TOR is unknown. Although TORC1 and TORC2 control 
different signaling processes within a cell, cell growth has to occur in a coordinated 
manner. Therefore both TOR complexes might respond to the same signal. Since 
LST8 is the only TOR-interacting protein present in both complexes it could be an 
important factor for sensing upstream signals. Data presented in Part 3 of this thesis 
indicate a function for LST8 upstream of TOR2 as overexpression of TOR2 weakly 
suppresses the growth phenotype of lst8 mutants. LST8 might therefore receive 
upstream signals and accordingly modulate the kinase activity of both TORC1 and 
TORC2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Model 
AVO1 and AVO3 act as scaffold and adaptor proteins maintaining the integrity of TORC2 and the 
association with downstream factors, like SLM1 and SLM2 to (TORC2). LST8 through binding to the C-
terminal part of TOR2 regulates kinase activity of TOR2. Oligomerization of TORC2 is not shown in this 
model. 
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4. 4. Materials and methods 
  
Strains, plasmids, and media 
The S. cerevisiae strains and plasmids used are listed in Table 4.1. and 4.2., 
respectively. All strains are isogenic derivatives of JK9-3da or TB50a. Rich media, YPD 
or YPGal/Gly, and synthetic complete media, SD or SGal/Gly, were as described 
previously (Beck et al., 1999; Sherman, 1991). Nitrogen starvation experiments were 
performed with synthetic media as previously described (Schmidt et al., 1998). For 
TOR2-, AVO1-, AVO3-, LST8-depletion experiments, cells from logarithmically growing 
SGal/Gly or YPGal/Gly cultures were inoculated into SD or YPD medium, respectively. 
Glucose cultures were shaken for 15 hr before cells were harvested for analysis. 
  
Genetic techniques 
Restriction enzyme digests and ligations were performed according to standard 
methods. All enzymes and buffers were obtained commercially (Roche Diagnostics). 
Escherichia coli strains MH1 and DH5α were used for propagation and isolation of 
plasmids. Yeast transformation was performed by the lithium acetate procedure (Ito et 
al., 1983). PCR cassettes were used to generate gene deletions and modifications, as 
described (Longtine et al., 1998; Puig et al., 2001). 
 
Immunoprecipitations and TAP pull-downs 
A 200 ml culture was grown in YPGal/Gly or YPD at 30°C for 15 hr to OD600 of 0.8, 
harvested by centrifugation and washed with cold water. The pellet was resuspended 
in 2 ml lysis buffer (1 x PBS, 10% glycerol, 0.5% Tween-20 plus inhibitors: 10 mM NaF, 
10 mM NaN3, 10 mM p-nitrophenylphosphate, 10 mM sodium pyrophosphate, 10 mM 
β-glycerophophate, 1 mM phenylmethylsulfonyl fluoride, 1 x Roche complete inhibitor 
cocktail). Cells were lysed by vortexing 5 x 30 s with glass beads using a FastPrep 
machine (Savant Instruments). Extracts were cleared with a 5 min, 2900 x g spin. An 
aliquot of extract containing 3 mg protein was adjusted to 1 ml with lysis buffer plus 
inhibitors. To immunoprecipitate the epitope tagged protein 1 µl of either concentrated 
12CA5 (anti-HA) or 9E10 (anti-myc) tissue culture supernatant was added and the 
tubes were rotated for 1 hr at 4°C. Afterwards 20 µl protein G-sepharose slurry (Sigma) 
was added and the tubes were rotated for additional 2 hr at 4°C. For TAP pull-downs 
20 µl IgG-sepharose 6 fast flow (Amersham Pharmacia Biotech) was added, and tubes 
were rotated for 3 hr at 4°C. Beads were collected by centrifugation, washed four times 
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with 1 ml lysis buffer, and resuspended in 2 x SDS-PAGE sample buffer. For 
coimmunoprecipitations the sample was split in half, one aliquot was used for 
expression control, the other half to detect the coimmunoprecipitated protein and 
subjected to SDS-PAGE. After electrophoresis the proteins were electroblotted onto 
nitrocellulose, blocked in 5% milk in 1 x PBS 0.1% Tween-20, and incubated with 
primary antibody (12CA5 or 9E10 1:10000 in blocking solution, or anti-ProteinA 1:5000 
in blocking buffer) over night at 4°C. The membranes were washed and incubated for 1 
hr at room temperature with the corresponding horseradish peroxidase-conjugated 
secondary antibody. The tagged proteins were detected using ECL reagents 
(Amersham Pharmacia Biotech). 
 
Purification of GST-tagged proteins 
XL-1 blue cells transformed with pGEX-4T::SLM1 were grown in 1 l LB/Amp at 37°C to 
an OD600 of 0.4 and expression of GST-SLM1 was induced by incubation with 0.4 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) for 3.5 hr at 37°C. Cells were lysed in lysis 
buffer (1 x PBS, 10% glycerol, 0.5% Tween-20, 1 mM phenylmethylsulfonyl fluoride, 1 
x Roche complete inhibitor cocktail) by sonication. Cleared extracts were incubated 
with 600 µl glutathione sepharose beads (Pharmacia) and rotated at 4°C for 3 hr. After 
washing with lysis buffer the protein was eluted with 10 mM reduced glutathione 
(Sigma) in 50 mM Tris-HCl (pH 8.0) and dialysed against 1 x PBS, 20% glycerol, 0.5% 
Tween-20. 
 
Kinase assays 
Cells expressing HA-TOR2 in different mutant backgrounds maintained on YPD and 
YPGal/Gly plates, respectively were inoculated into YPGal/Gly liquid media and 
cultured over night. Per strain (4 assays) 4 l of YPD were inoculated and grown at 30°C 
for 15 h to an OD600 of 0.8 and the chilled on ice for 30 min. Cells were collected by 
centrifugation, washed once in ice-cold water and lysed with a Bead Beater (Biospec 
products) in ~20 ml lysis buffer (1 x PBS, 10% glycerol, 0.5% Tween-20 plus inhibitors: 
10 mM NaF, 10 mM NaN3, 10 mM p-nitrophenylphosphate, 10 mM sodium 
pyrophosphate, 10 mM β-glycerophophate, 1 mM phenylmethylsulfonyl fluoride, 1 x 
Roche complete inhibitor cocktail).  The lysate was cleared with a 5 min, 2900 x g spin. 
Lysates were normalized to ~20 ml and ~300 mg protein per strain (4 kinase reactions) 
and passed over 200 µl Sepharose CL-4B (Sigma) : ProteinA-sepharose (Amersham) 
(3:1), which has been previously equilibrated in lysis buffer. To the flow through was 
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added 150 µl anti-HA crosslinked to Protein A-sepharose beads. This mixture was 
rotated for 3 hr at 4°C after which time the beads were collected in a column and 
washed with 30 ml lysis buffer. Antibody-beads were equally split amongst 5 tubes. To 
one aliquot 30 µl 2 x SDS-PAGE sample buffer was added and was used for western 
blotting. To the remaining aliquots either GST-LIT2 ranging from 0.1 - 2.7 µM or 4E-
BP1 (Stratagene) ranging from 0.15 - 4.05 µM in 50 µl kinase buffer (lysis buffer with 
20% glycerol). For time course experiments 30 µg GST-LIT2 or 1 µg 4E-BP1 was 
added. 6 µl of 10 x goodies (40 mM MnCl2, 100 mM dithiothreitol, 10 x Roche complete 
inhibitor cocktail - EDTA, 100 mM NaN3, 100 mM NaF, 100 mM p-
nitrophenylphosphate, 100 mM β-glycerophosphate) were added before the reaction. 
The kinase reaction was started with the addition of 4 µl ATP mix (1.2 mM ATP, 2.5 
µCi/ µl γ32P-ATP [3000 Ci/mmol] in kinase buffer. Tubes were mixed (1200 rpm) at 
30°C (incubation time for reactions with GST-LIT2: 20 min, incubation time for 
reactions with 4E-BP1: 10 min). The reactions were terminated with the addition of 15 
µl 5 x SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE (5-20%) and 
radioactivity was quantified using GeneSnap software (SynGene). 
 
 
Table 4.1. Strains  
 
Strain  Genotype 
 
JK9-3da MATa leu2-3,112 ura3-52 trp1 his4 rme1 HMLa 
JK9-3dα MATα leu2-3,112 ura3-52 trp1 his4 rme1 HMLα 
TB50a  JK9-3da HIS4 his3 
TB50α  JK9-3dα HIS4 his3 
RL39-1a TB50a AVO2-3HA-kanMX4 
RL42-1c TB50a AVO3-3HA-kanMX4 
RL59-2d TB50a LST8-13myc-kanMX4 
RL69-1c TB50a AVO1-3HA-kanMX4 
SW62-7a TB50a HA-TOR2 AVO3-13myc-kanMX4 
SW63-1d TB50α HA-TOR2 LST8-13myc-kanMX4 
SW65-11c TB50a [HIS3MX6]-GAL1p-AVO3 AVO1-3HA-kanMX4 AVO2-13myc-
kanMX4 
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SW67-3b TB50α [HIS3MX6]-GAL1p-AVO3 AVO1-3HA-kanMX4 LST8-13myc-
kanMX4 
SW68-3b TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2 AVO3-13myc-kanMX4 
SW69-4d TB50a [HIS3MX6]-GAL1p-AVO1 LST8-3HA-kanMX4 AVO2-13myc-
kanMX4 
SW70  TB50a 3HA-TOR2 
SW72-5a TB50a [HIS3MX6]-GAL1p-AVO3 3HA-TOR2 AVO2-13myc-kanMX4 
SW73-4b TB50a [HIS3MX6]-GAL1p-AVO1 AVO3-3HA-kanMX4 AVO2-13myc-
kanMX4 
SW74-11b TB50a [HIS3MX6]-GAL1p-AVO1 LST8-3HA-kanMX4 AVO3-13myc-
kanMX4 
SW75-10c TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2 LST8myc-kanMX4 
SW76-5b TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2 AVO2-13myc-kanMX4 
SW77-5d TB50a [HIS3MX6]-GAL1p-AVO3 3HA-TOR2 LST8-13myc-kanMX4 
SW78-3a TB50a [HIS3MX6]-GAL1p-AVO3 LST8-3HA-kanMX4 AVO2-13myc-
kanMX4 
SW84-1d TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2  
SW92-5a TB50a 3HA-TOR2 avo2::kanMX4 
SW94-1a TB50a [HIS3MX6]-GAL1p-TOR2 AVO3-13myc-kanMX4 
SW100-1a TB50a [HIS3MX6]-GAL1p-LST8 3HA-TOR2  
SW102-8b TB50a avo2::kanMX4 3HA-TOR2 AVO3-13myc-kanMX4 
SW103-2d TB50α avo2::kanMX4 3HA-TOR2 LST8-13myc-kanMX4 
SW104-3c TB50a [kanMX4]-GAL1p-LST8 3HA-TOR2 AVO3-13myc-kanMX4 
SW105-3d TB50α [HIS3MX6]-GAL1p-TOR2 AVO1-3HA-kanMX4 AVO3-13myc-
kanMX4 
SW106-5a TB50a [HIS3MX6]-GAL1p-TOR2 AVO1-3HA-kanMX4 AVO2-13myc-
kanMX4 
SW108-4a TB50α [kanMX4]-GAL1p-LST8 3HA-TOR2 AVO2-13myc-kanMX4 
SW109-3d TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2 LST8-13myc-kanMX4 
KOG1-TAP-kanMX4 
SW110 TB50a/α AVO1-3HA-kanMX4 AVO1-TAP-KlTRP1 
SW111 TB50a/α AVO2-3HA-kanMX4 AVO2-13myc-kanMX4 
SW112 TB50a/α AVO3-3HA-kanMX4 AVO3-13myc-kanMX4 
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Table 4.2. Plasmids 
 
Plasmids Description 
 
pAN54  expresses myc-tagged TOR2 from TOR2 promoter, YCplac111::myc-
TOR2 (CEN, LEU2) 
pRL42-1 expresses GST-tagged SLM1 (YIL105c), pGEX-4T::SLM1 
pSW61  expresses HA-tagged TOR2 (1-1390) from TOR2 promoter. Cloned as 
4.7-kb BamHI-PstI fragment into YEplac195::CYC1 terminator (2µ, 
URA3) 
pSW62  expresses HA-tagged TOR2 (1290-2474) from TOR2 promoter. Cloned 
as 4.1-kb SacI-PstI fragment into YEplac195::TOR2 promoter ATG-3HA 
(2µ, URA3) 
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5. TOR and its role as protein kinase 
 
5. 1. Introduction 
 
TOR as protein kinase 
TOR is the founding member of phosphatidylinositol kinase-related kinases (PIKK) 
family of protein kinases (Keith and Schreiber, 1995). PIKKs share similarity to the 
kinase domain of phosphatidylinositol kinases (PIK), but none of them are believed to 
act as a lipid kinase. Rather, PIKKs are thought to act as Ser/Thr protein kinases. TOR 
too is a protein kinase as immunoprecipitated mTOR autophosphorylates (Brunn et al., 
1996; Chen et al., 1995) and is able to phosphorylate 4E-BP1 and p70S6K in vitro 
(Brunn et al., 1997; Burnett et al., 1998). The phosphorylation occurs in an mTOR-
dependent manner since mTOR containing a point mutation changing Asp2338 to Ala 
shows no kinase activity. This Asp residue is conserved in both protein and lipid 
kinases, where it is required for kinase activity (Hunter, 1995). Mutation of Asp2338 to 
Ala also inhibits mTOR autophosphorylation on Ser2481 (Peterson et al., 2000). 
 
In vitro mTOR has been reported to phosphorylate five sites in p70S6K, Ser371, 
Thr389, Thr421, Ser424, and possibly Ser411, with Thr389 being the preferred site 
(Burnett et al., 1998; Isotani et al., 1999; Saitoh et al., 2002). 4E-BP1 is phosphorylated 
at two sites by mTOR in vitro, Thr37 and Thr46 (Brunn et al., 1997; Fadden et al., 
1997; Gingras et al., 1999). The phosphorylation sites fall into two different groups. The 
hydrophobic motif, Thr389-Tyr, and the Ser/Thr-Pro motif found in all the other 
phosphorylation sites of p70S6K and 4E-BP1. Since there is no common recognition 
motif in the amino acid sequence of mTOR substrates, other structural determinates or 
accessibility of substrates to mTOR mediated by protein-protein interactions might also 
be important for an efficient phosphorylation of substrates. Nevertheless, an effect of 
so far unknown kinases or phosphatases which associate to mTOR or are regulated by 
mTOR can also not be ruled out. 
 
In yeast the function of TOR1 and TOR2 as protein kinases is unclear. Although TOR1 
and TOR2 are able to phosphorylate 4E-BP1 (Alarcon et al., 1999), direct substrates 
for the TOR kinases in yeast have not been reported until very recently (Audhya et al., 
2004). It is well established that TORC1 controls at least some of the rapamycin-
sensitive readouts via inhibition of phosphatases (Schmelzle and Hall, 2000). Under 
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good nutrient conditions TORC1 inhibits the phosphatase SIT4 by promoting its 
association with TAP42. Upon inhibition of TORC1, either by rapamycin or nitrogen 
starvation, catalytically active SIT4 is released from TAP42 promoting the 
dephosphorylation of its target proteins such as the protein kinase NPR1, the 
transcription factor GLN3 and the TAP42 interacting protein TIP41. TOR1 has been 
reported to control the association of SIT4 to TAP42 via direct phosphorylation of 
TAP42 (Jiang and Broach, 1999), however this result remains controversial. The 
protein TIP41 was identified in a yeast two-hybrid screen as an interactor of TAP42 
(Jacinto et al., 2001). TIP41 is a negative regulator of the TOR signaling pathway and 
mediates inhibition of the TOR signaling pathway by binding and inhibiting TAP42. 
Upon rapamycin treatment TIP41 is dephosphorylated in a SIT4-dependent manner 
leading to an enhanced binding of TIP41 to TAP42 and thereby inactivating TAP42 and 
amplifying SIT4 phosphatase activity. Since the phosphorylation status of TIP41 and 
NPR1 is regulated in a TOR-dependent manner it has been suggested that TOR might 
directly, or via a TOR-regulated kinase, control the phosphorylation of these proteins. 
Recently, the phosphorylation sites of NPR1 were identified (D. Bonenfant 
unpublished). NPR1 contains 22 rapamycin-sensitive phosphorylation sites and the 
motifs of these sites are similar to the rapamycin-sensitive sites in p70S6K and 4E-
BP1. However, in vitro kinase assays indicated that TOR1 does not directly 
phosphorylate NPR1 suggesting that another kinase phosphorylates NPR1 and TOR 
may control the phosphorylation status of NPR1 exclusively via the phosphatase SIT4. 
 
  
 
Analysis of phosphorylation sites  
Identification of phosphorylation sites is still challenging despite recent advances in 
methodology. The most commonly used technique to analyze a phosphoprotein 
involves in vivo or in vitro labelling with 32P-phosphate. The radiolabelled protein is then 
digested with a protease and the peptides are separated either by high performance 
liquid chromatography or by two-dimensional phosphopeptide mapping. The 
phosphorylation site is then determined by Edman sequencing. Alternatively, 
phosphorylation sites can also be traced by using mass spectrometric methods. The 
analysis of proteins by mass spectrometry involves proteolytic digestion of the protein 
of interest, which is followed by measuring the mass of the generated peptides. The 
different peptides are then identified by comparing the observed masses obtained by 
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mass spectrometry to the predicted masses based on the specificity of the protease 
that was used to digest the protein of interest. Singly phosphorylated peptides exhibit a 
mass that is 80 Da greater than the predicted mass from the peptide sequence since 
they contain an HPO4 group. The phosphorylation site in a phosphopeptide can be 
determined by fragmentation of the peptide in the collision cell of the mass 
spectrometer (Bonenfant et al., 2003a). A major problem of this method is the 
complexity of the data that increases with the molecular weight of the protein. In 
addition, electrospray ionization produces multiple signals for each peptide due to 
multiple charging. To reduce the complexity procedures have been developed to detect 
phosphopeptides in a selective manner. One of these methods involves the enrichment 
of phosphopeptides in a complex mixture by immobilized metal-affinity chromatography 
(IMAC) (Ficarro et al., 2002). IMAC beads selectively bind phosphopeptides which can 
be eluted from the beads with Tris-buffer (pH 8.0) or alkaline phosphatase treatment. 
The eluted peptide is then analyzed by mass spectrometry. 
 
 
Identification of substrates for a specific kinase 
There are different procedures to identify a substrate for a kinase of interest. One 
approach, called KESTREL (kinase substrate tracking and elucidation) is based on a 
kinase reaction using cell extracts and the kinase of interest in the presence of 32P-ATP 
(Knebel et al., 2001). Another assay makes use of ATP derivates that can only be used 
as substrates by mutated forms of the protein kinase of interest (Bishop et al., 2001). 
 
The major problem performing a kinase reaction with whole cell extract and the kinase 
of interest is the high background due to endogenous kinases that are present in the 
cell extract. In KESTREL the conditions of the kinase assay have been optimized 
resulting in a reduction of the background (Knebel et al., 2001). To maximize the 
sensitivity of the kinase reaction ATP-depleted cell extracts are incubated with a high 
concentration of the kinase of interest using 32P-ATP of high specific radioactivity. The 
incubation time is kept short and the use of MnATP instead of MgATP is preferred at 
least for kinases that can use both forms of ATP with similar efficiency. In addition, 
performing the kinase reaction with cell extract that is purified prior to the kinase 
reaction by a single step purification, such as ion-exchange chromatography minimized 
the signal to noise ratio. The substrates are detected by autoradiography and are 
further purified in order to be identified by mass spectrometry.  
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Another method was developed by the group of Kevan Shokat (Bishop et al., 2001). 
This approach allows the specific labelling of the substrates of a kinase of interest in 
the cell extract. The method is based on the mutation of a conserved bulky residue in 
the ATP-binding pocket of a given kinase to a glycine or alanine. Only this mutated 
kinase is then able to bind bulky ATP analogues that fit into the mutant-binding pocket 
but cannot bind to wild-type kinases. A kinase reaction can be performed using cell 
extract that contains a single analogue-sensitive kinase and the radiolabelled ATP-
analogue resulting in the specific labelling of the direct substrate of the kinase of 
interest, as only this modified kinase is able to use the ATP-analogue to phosphorylate 
its substrate. However, computer-based modelling of the active site of the kinase as 
well as elaborate chemical synthesis of the analogues is required for the design of the 
ATP-analogues. 
 
Here we focus on TOR and its role as a protein kinase in yeast. We tried to map TOR-
regulated phosphorylation sites in TIP41 as well as AVO1 and AVO3 by mass 
spectrometric methods. To gain further insight into TOR signaling we started to develop 
an assay to identify substrates for the TOR kinases. This work was done in 
collaboration with Paul Jenoe, Division of Biochemistry, Biozentrum, Basel. 
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5. 2. Results 
 
Phosphorylation of TIP41 
To map phosphorylation sites TIP41 was expressed as a GST-tagged fusion protein 
from a GAL1 promoter-containing plasmid in yeast cells. After 2 hours induction with 
galactose GST-TIP41 was purified via glutathione-affinity chromatography, and the 
protein was digested with either trypsin or endoprotease LysC. The generated peptides 
were analyzed by electrospray mass spectrometry (LC/MS) and compared to the 
predicted masses based on the specificity of the protease. Combining trypsin and LysC 
digestion 90% of the peptides were observed in the LC/MS analysis missing only one 
Ser or Thr containing peptide. Examining the spectra for the presence of peptides 
whose masses were increased by 80 Da (or multiples thereof), two candidates were 
found: peptide T39 and T40 (data not shown). Alternatively, the tryptic fragments of 
GST-TIP41 were subjected to IMAC (immobilized metal-affinity chromatography) 
selection. IMAC-beads charged with Fe3+ selectively bind phosphopeptides. The bound 
peptides were eluted from the IMAC-beads with Tris-buffer (pH 8.0) and analyzed by 
MALDI-TOF mass spectrometry. Three candidate phosphopeptides were identified: 
T39, T38-39, T40 (T38-39 represents an incompletely digested peptide) confirming the 
results obtained by LC/MS analysis (Fig. 5.1.). When elution from the IMAC-beads was 
performed in the presence of alkaline phosphatase, the mass of the three peptides 
decreased by 80 Da indicating that the peptides selected by IMAC are indeed 
phosphorylated (Fig. 5.1.). 
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Figure 5.1. IMAC phosphopeptide selection from tryptic digest of GST-TIP41.  
A) MALDI-TOF spectrum of T39 and T38-39 phosphopeptides eluted from IMAC beads in presence of 
Tris-buffer (pH 8.0) (upper spectrum) or in presence of alkaline phosphatase (AP) (lower spectrum).  
 
B) MALDI-TOF spectrum of T40 phosphopeptide eluted from IMAC beads in presence of Tris-buffer (pH 
8.0) (upper spectrum) or in the presence of alkaline phosphatase (AP) (lower spectrum) 
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To determine the precise phosphorylation sites the phosphorylated peptides T39 and 
T40 were analyzed by electrospray ionisation tandem mass spectrometry (LC-MS/MS). 
Ions of the specific peptide (T39 or T40) were selected in the first quadrupole of the 
mass spectrometer and subsequently subjected to fragmentation in the collision cell 
leading to the generation of ions from which the sequence of the peptide can be 
deduced. Phosphorylated fragment ions can be identified by a shift of 80 Da (or divided 
by the corresponding charge state of the fragment ions). Comparing the MS/MS 
spectra of the phosphorylated peptide with its unphosphorylated counterpart allows one 
to pinpoint the residue from which the mass shift occurred. We identified Thr55 and 
Ser79 as phosphorylation sites of TIP41 (data not shown). 
 
The function and the rapamycin-sensitivity of the two phosphorylation sites remain to 
be elucidated. However, the two phosphorylation sites identified possess a Ser/Thr-Pro 
motif that is similar to rapamycin-sensitive sites in p70S6K, 4E-BP1 and NPR1. Since 
mTOR is thought to directly phosphorylate p70S6K and 4E-BP1 we suggested that 
TIP41 is phosphorylated by the TOR kinases. To investigate this possibility in vitro 
kinase assays with TOR complex 1 (TORC1) and bacterial expressed GST fusion 
proteins of wild-type TIP41 and TIP41(81-355) lacking the N-terminal phosphorylation 
sites were carried out. No phosphorylation of wild-type TIP41 or TIP41(81-355) was 
observed leading to the conclusion that TIP41 is likely phosphorylated by a kinase 
other than TOR1/2 (data not shown). 
 
 
AVO1 and AVO3 are phosphoproteins 
AVO1 and AVO3 appear to be phosphorylated by TORC2 in vitro (R. Loewith, W. 
Oppliger unpublished). The other proteins of TORC2, BIT61 and AVO2 were 
phosphorylated to a minor extent, whereas LST8 was not phosphorylated (Fig. 5.2.A). 
To test whether phosphorylation of AVO1 and AVO3 is dependent on TOR2, kinase 
assays with a kinase dead version of TOR2 (TOR2-KD) were performed. 
Phosphorylation of AVO1 and AVO3 was decreased in a TOR2-KD strain indicating 
that TOR2 is responsible for in vitro phosphorylation of AVO1 and AVO3 (Fig. 5.2.B).  
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Figure 5.2. AVO1 and AVO3 are phosphorylated in a TOR2-dependent manner 
A) In vitro kinase assays were performed using immunopurified TORC2 from wild-type (SW70), avo2 
(SW92-5a) or GAL1 promoter-AVO1 (SW84-1d) containing cells grown in glucose medium for 15 hr to 
deplete AVO1. As a control mock purification of untagged strain (TB50a) was performed.  
 
B) In vitro kinase assays were performed using TORC2 purified from TAP-tagged AVO2 GAL1 promoter-
TOR2 (SW80-1d) transformed with either empty plasmid (lane 1, mock), pHA-TOR2 (lane 2) or pHA-
TOR2-KD (lane 3). Cells were grown for 16 hr in glucose medium to deplete endogenous TOR2. Upper 
panel: phosphorylation of AVO1 and AVO3, lower panel: expression of HA-TOR2 (lane 2) or HA-TOR2-KD 
(lane 3) detected by immunoblotting. 
 
 
 
To identify the TORC2-mediated phosphorylation sites of AVO1 and AVO3 we 
developed an assay in which the phosphorylation sites of AVO1 and AVO3 were 
labelled with 32P, subsequently isolated and analyzed by mass spectrometry. To label 
the phosphorylation sites of AVO1 and AVO3 TORC2 was purified with a TAP-tagged 
version of AVO2 and subjected to kinase reaction in the presence of 32P-ATP. After gel 
electrophoresis the radioactive AVO1 and AVO3 bands were cut and proteolytic 
cleaved by trypsin. The peptides were separated on a reverse-phase column and the 
amount of radioactivity was determined. The fractions containing high amount of 
radioactivity representing phosphorylated peptides were analyzed by MALDI-TOF 
mass spectrometry. We were not able to obtain reproducible results using this 
approach. The major problems were first the low abundance of AVO1 and AVO3 and 
second the low stoichiometry of the phosphorylation making it very difficult to identify 
phosphorylated peptides.  
(This part was done in collaboration with P. Jenoe, R. Loewith, W. Oppliger) 
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Approach to identify substrates of TOR2 
To identify substrates of TORC2 an approach similar to KESTREL was developed. To 
eliminate the background due to endogenous protein kinases we chemically digested 
yeast protein extract with cyanogenbromide (CNBr) to fragment and inactivate 
endogenous protein kinases. Yeast extracts were prepared in the absence of 
phosphatase inhibitors to ensure that potential substrates are present in an 
unphosphorylated from. SDS was included to solubilize membrane proteins. To remove 
SDS the proteins were precipitated by deoxycholate-TCA precipitation and 
subsequently digested with CNBr. Since methionine is a rare amino acid we expected 
to obtain relatively large peptides ensuring that the structural determinants for substrate 
recognition would be preserved. The CNBr digest was fractionated by reverse-phase 
chromatography. Separate fractions were incubated with purified TORC2 in the 
presence of 32P-ATP and subjected to electrophoresis on Tris-tricine gels. In a control 
experiment a mock kinase assay was performed to validate the specificity of the 
approach (Fig. 5.3.A). Radiolabelled bands specifically phosphorylated by TORC2 
demonstrate the feasibility of the approach (Fig. 5.3.B; band 1 to 5). Preliminary 
analysis of the radioactive band 5 by MALDI-TOF revealed that the band contained a 
mixture of several proteins consisting of heat shock proteins SSA1 and SSB1, the two 
ribosomal proteins RS9A and RS7B, pyruvate kinase PYK1, and the inorganic 
diphosphatase IPP1. However, further purification of the bands using chromatographic 
methods is required to clarify the identity of the labelled protein. 
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Figure 5.3. TORC2 in vitro kinase assays with a CNBr peptide library generated  
from wild-type strain (TB50a).  
TORC2 was purified from strain RL126-5d expressing TAP-tagged AVO2 and incubated with different 
fractions of a CNBr digest of yeast protein extract that was chromatographed on a reverse-phase column. 
A) Autoradiograph of kinase assays from mock purification (untagged strain) 
B) Autoradiograph of kinase assays from TORC2 purification. 
 
 
 
 
5. 3. Discussion 
 
To study the role of TOR as a protein kinase we analyzed the TOR-dependent 
phosphorylation sites of TIP41 by mass spectrometric methods. We identified two 
phosphorylation sites at the N-terminus of TIP41, Thr55 and Ser79. However, the 
stoichiometry of the phosphorylation appeared to be quite low and we had problems to 
confirm the phosphorylation sites when we analyzed TIP41 expressed from its own 
promoter instead of using TIP41 overexpressed from a galactose inducible plasmid. 
Whether or not the identified phosphorylation sites are rapamycin-sensitive, and also 
the in vivo role of these sites remain to be elucidated. TIP41 is a conserved protein, but 
the function of its homologue in higher eukaryotes has not been studied so far. The N-
terminal part of TIP41 that contains the identified phosphorylation sites is not 
conserved indicating that the phosphorylation sites are also not conserved. Which 
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kinase phosphorylates TIP41 remains unknown, as TORC1 did not directly 
phosphorylate TIP41 in vitro. Thus, TORC1 may only control phosphorylation of TIP41 
via SIT4 phosphatase whereas another kinase phosphorylates TIP41. A similar 
situation is observed in 4E-BP1 where rapamycin sensitivity of phosphorylation sites 
not always correlates with the ability of TOR to phosphorylate these sites in vitro 
(Gingras et al., 2001). It is therefore likely, that rapamycin-sensitive sites are not only 
directly phosphorylated by TOR but also controlled by TOR-regulated kinases or 
phosphatases.  
  
We encountered similar problems analyzing the phosphorylation of AVO1 and AVO3. 
The stoichiometry of the phosphorylation as well as the expression level of these 
proteins appeared to be too low to obtain reproducible results. Since AVO1 and AVO3 
were phosphorylated in a TOR2-dependent manner in vitro AVO1 and AVO3 might be 
direct targets of the TOR2 protein kinase. Phosphorylation of these two proteins might 
be important for downstream signaling events such as attachment of other substrates 
to TORC2. The significance of AVO1 and AVO3 phosphorylation and the in vivo role of 
these phosphorylations remain to be elucidated. 
 
To identify novel substrates for the TOR kinases we performed in vitro kinase assays 
using a yeast peptide library. We identified 5 bands that were phosphorylated in 
TORC2-dependent manner. One band was analyzed and as expected it contained a 
mixture of proteins which are highly expressed. It should be noted that no attempts 
were made to specifically isolate the radioactively labelled peptides that would reveal 
the identity of the labelled protein(s), but could be carried out by reverse-phase 
chromatography. However, identifying the inorganic diphosphatase IPP1 in the 
radiolabelled band is interesting, since it has been recently reported that 
polyphosphates may play a regulatory role in the activation of mTOR (Wang et al., 
2003). The developed assay appears to be feasible and can also be applied to identify 
substrates of other protein kinases. 
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5. 4. Material and Methods 
 
Strains, plasmids, and media 
The S. cerevisiae strains and plasmids used are listed in Table 5.1. and 5.2. 
respectively. All strains are isogenic derivatives of JK9-3da or TB50a. Rich media, YPD 
or YPGal/Gly, and synthetic complete media, SD or SGal/Gly, were as described 
previously (Beck et al., 1999; Sherman, 1991). For TOR2-, and AVO1-depletion 
experiments, cells from logarithmically growing SGal/Gly, SRaf/Gly or YPGal/Gly 
cultures were inoculated into SD or YPD medium, respectively. Glucose cultures were 
shaken for 15 hr before cells were harvested for analysis. 
  
Genetic techniques 
Restriction enzyme digests and ligations were performed according to standard 
methods. All enzymes and buffers were obtained commercially (Roche Diagnostics). 
Escherichia coli strains MH1 and DH5α were used for propagation and isolation of 
plasmids. Yeast transformation was performed by the lithium acetate procedure (Ito et 
al., 1983). PCR cassettes were used to generate gene deletions and modifications, as 
described (Longtine et al., 1998; Puig et al., 2001) 
 
Protein purification 
TB50a cells transformed with pGAL-GST-TIP41 (pSW63) were grown in SRaf/Gly-leu 
to an OD600 of 0.4. Expression of GST-TIP41 was induced by adding galactose (2% 
end concentration) and incubated for 2 hr at 30°C. Extracts prepared as described 
below were passed over a column packed with glutathione Sepharose 4B (Amersham 
Biosciences) which had been equilibrated with lysis buffer. After washing the column 
thoroughly with 100 mM Tris, pH 8.0, 150 mM NaCl, GST-TIP41 was eluted from the 
column with 100 mM Tris, pH 8.0, 150 mM NaCl containing 10 mM reduced glutathione 
(Sigma). The purity of the protein was checked by SDS polyacrylamide gel 
electrophoresis. The protein pool was divided into equal aliquots and stored at -20°C. 
Purification of bacterial expressed proteins was performed as described in part III. 
 
Peptide Nomenclature 
Peptides generated by trypsin cleavage are labelled with T. The peptides are 
numbered sequentially according to their position based on the N-terminal methionine 
of GST-TIP41. 
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Mass spectrometry 
Enzymatic digestions and LC-MS and LC-MS/MS was performed as described 
(Schneider et al., 1999). Selection of phosphopeptides and MALDI-TOF was performed 
as described (Bonenfant et al., 2003b). 
 
Generation of yeast peptide library 
Wild-type cells (TB50a) were grown in 50 ml YPD to OD600 of 0.6, collected by 
centrifugation and resuspended in 0.5 ml lysis buffer (100 mM Tris, pH 7.5, 150 mM 
NaCl, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 1 x Roche complete inhibitor 
cocktail). Cells were lysed by vortexing 5 x 30 s with glass beads using a FastPrep 
machine (Savant Instruments). Extracts were cleared with a 5 min, 2900 x g spin and 
dialysed with a Float-A-Lyzer (10000 Da MWCO, Spectrum Labs) against 100 mM Tris, 
pH 7.5, 150 mM NaCl, 0.1% SDS. Per 100 µl homogenate 2.2 µl Na-deoxycholate (10 
mg/ml) was added and incubated on ice for 30 min. Proteins were precipitated by 
adding 42 µl 20% TCA per 100 µl homogenate, 30 min on ice After centrifugation at 
12000 rpm for 5 min, SDS was extracted from the pellet with three 1 ml washes of 
acetone-acetic acid-triethylamine 90:5:5. Afterwards the pellet was dried in a speed vac 
(Konigsberg and Henderson, 1983). The protein pellet was solubilized in formic acid. 
Final concentration of formic acid was brought to 70% with water. To cleave the 
proteins an excess of white crystalline cyanogen bromide to between 2- and 100-fold 
molar excess over methionyl residues was added and incubated at room temperature 
for 24 h. The reaction was terminated by injecting it onto an RP-HPLC for desalting. 
RP-HPCL was performed using a Vydac 214TP52 column with a 60 min gradient 
consisting of 0.4 – 76% acetonitrile in 0.1% TFA at flow rate of 100 µl/min, collecting 
fractions every minute. 
 
Kinase assays 
SW80-1d cells transformed with either empty plasmid, pHA-TOR2 or pHA-TOR2-KD 
were inoculated into SRaf/Gly-trp liquid media and cultured over night. 5 l of SD-trp 
were subsequently inoculated to an initial OD600 of 0.008. Cultures were grown at 30°C 
for 16 hr (to an OD600 of ~1.0) and then chilled on ice for 30 minutes. Cells were 
collected by centrifugation, washed once in ice-cold water and lysed (7 x 30 sec) with a 
Bead Beater (Biospec products) in ~40 ml lysis buffer (1 x PBS, 10% glycerol, 0.5% 
Tween-20 plus inhibitors: 10 mM NaF, 10 mM NaN3, 10 mM p-nitrophenylphosphate, 
10 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1 mM 
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phenylmethylsulfonyl fluoride, 1 x Roche complete inhibitor cocktail). Glass beads (0.5 
mm) were washed with an additional 10 ml of lysis buffer with inhibitors and pooled 
lysates were cleared with a 5 min., 2900 x g spin. Lysates were normalized to ~50 ml 
and ~375 mg protein and passed over 125 µl of Sepharose CL-4B (Sigma) which had 
been previously equilibrated in lysis buffer. To the flow through was added 150 µl IgG-
Sepharose (Amersham Bioscience; prewashed with lysis buffer). This mixture was 
rotated for 2 hr at 4°C after which time the beads were collected in a column and 
washed with 45 ml lysis buffer. IgG beads from each of the three strains were then 
equally split to two 1.5 ml eppendorf tubes and all liquid was removed with a Hamilton 
syringe. To one aliquot from each of the three strains was added 30 µl 1 x SDS-PAGE 
sample buffer. These samples were used for western blotting. To the remaining beads 
were added 50 µl kinase assay buffer (lysis buffer with 20% glycerol) and 6 µl of 10 x 
goodies (40 mM MnCl2, 100 mM dithiothreitol, 10 x Roche Protease inhibitor cocktail - 
EDTA, 100 mM NaN3, 100 mM NaF, 100 mM p-nitrophenylphosphate, 100 mM β-
glycerophosphate). The reaction was started with the addition of 4 µl ATP mix (1.2 mM 
ATP, 2.5 µCi/µl γ32P-ATP [3000 Ci/mmol] in kinase buffer). Tubes were mixed (1200 
rpm) at 30°C and the reactions were terminated after 10 min with the addition of 15 µl 5 
x SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE (5-20%) and 
radioactivity was quantified using GeneSnap software (SynGene). Kinase assays using 
TORC2 purified from TAP-tagged AVO2 strain (RL126-5d) were performed 
accordingly. Purification of HA-TOR2 by immuno-affinitiy was performed as described 
in Part 4. 
 
 
Table 5.1. Strains 
 
Strain  Genotype 
 
JK9-3da MATa leu2-3,112 ura3-52 trp1 his4 rme1 HMLa 
TB50a  JK9-3da HIS4 his3 
SW80-1d TB50a [HIS3MX6]-GAL1p-TOR2 AVO2-TAP-kanMX4 
RL126-5d TB50a AVO2-TAP-KlTRP1 
SW70  TB50a 3HA-TOR2 
SW84-1d TB50a [HIS3MX6]-GAL1p-AVO1 3HA-TOR2  
SW92-5a TB50a 3HA-TOR2 avo2::kanMX4 
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Table 5.2. Plasmids 
 
Plasmids   Description  
 
pHA-TOR2 expresses HA-tagged TOR2 from TOR2 promoter; 
pRS314::3HA-TOR2 (CEN, TRP1) (Jiang and Broach, 
1999) 
pHA-TOR2-KD expresses HA-tagged TOR2-kinase dead from TOR2 
promoter; pRS314::3HA-TOR2D2998E (CEN, TRP1) (Jiang 
and Broach, 1999) 
pGAL-GST-TIP41 pSW63; expresses GST-TIP41 under the control of the 
GAL1 promoter. Cloned as 1.1-kb BamHI-SalI fragment 
into YCplac111::GAL1 promoter-GST (CEN, LEU2). 
pGST-TIP41   pEJ122; pGEX-4T::TIP41 
pGST-TIP41(81-355) pSW36; TIP41 (nt 243-1065) cloned as 0.8-kb BamHI-
SalI fragment into pGEX-4T 
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6. Perspectives 
TOR is a major controller of cell growth in S. cerevisiae. TOR signaling is rather 
complex and includes regulation of many different pathways. The identification of two 
distinct TOR complexes, TORC1 and TORC2 begins to explain how specificity and 
diversity is achieved in TOR signaling. Given the fact that components of the TOR 
complexes stably interact with each other suggests that a major role of these proteins 
is to maintain structural integrity of the complex. Indeed, our data on TORC2 indicate 
that AVO1 and AVO3 are required for the stability of the complex and also function as 
adaptor proteins required for recruitment of substrates for TORC2.  
 
What are the substrates of the TOR kinases in yeast? The knowledge about 
downstream processes controlled by TOR has rapidly increased over the past few 
years. However, direct substrates of the TOR protein kinases have not been found until 
very recently in yeast (Audhya et al., 2004). We identified several candidate substrates 
of the TOR2 kinase. One possible substrate is YPK2 and it would be interesting to 
study the role of YPKs in TOR signaling. In analogy to the situation in higher 
eukaryotes and S. pombe, YPKs have already been implicated to act as potential 
substrates for TOR, however, how YPKs signal to downstream effector pathways such 
as the PKC1-MAP kinase cascade is not understood. Other putative substrates of 
TOR2 include proteins within TORC2, such as AVO1 and AVO3, which are both 
phosphorylated in a TOR2-dependent manner in vitro. The in vivo role of AVO1 and 
AVO3 phosphorylation is unknown. In this respect it would be interesting to map the 
phosphorylation sites of these two proteins. Mutation of the phosphorylation sites into 
phosphomimetic and non-phosphorylatable sites would clarify the significance of these 
phosphorylation events in vivo. Phosphorylation of AVO1 and AVO3 could create a 
docking site for substrates of TORC2. Applying a proteomic approach using yeast 
peptide library as described in Part 5 could lead to the identification of potential 
substrates for TORC1 and TORC2. 
 
How is TOR signaling regulated in response to nutrients? Our work suggests that LST8 
modulates TOR2 kinase activity, possibly through binding directly to the kinase domain 
of TOR2. Since LST8 is present in both complexes it is likely that LST8 also regulates 
kinase activity of TORC1. TORC1 and TORC2 might therefore respond to upstream 
signals through LST8, whereas specificity of downstream signaling events is 
determined by the different partner proteins of both complexes. 
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